Code	Indication	Categories	Regimen	URL
00254b	"Adjuvant treatment of hormone receptor positive early invasive breast cancer in post-menopausal women.
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer."	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	anastrozole	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf
00254c	"Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen."	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	anastrozole	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf
00216f	Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	capecitabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdf
00348a	Neoadjuvant treatment of triple negative breast carcinoma.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	carboplatin (auc6) and weekly paclitaxel (80mg/m2) followed by dose dense doxorubicin cyclophosphamide therapy-triple negative breast cancer	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/348.pdf
00381a	Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	cyclophosphamide (iv) methotrexate and 5-fluorouracil (cmf) therapy 21 day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/381.pdf
00378a	Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	cyclophosphamide (iv) methotrexate and 5-fluorouracil (cmf) therapy 28 day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/378.pdf
00377a	Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	cyclophosphamide (oral) methotrexate and 5-fluorouracil (cmf)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/377.pdf
00250a	Adjuvant treatment of patients with high risk node-positive or node-negative early operable breast cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	docetaxel/cyclophosphamide (tc) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/250-docetaxel-cyclophosphamide-tc-therapy-21-day.pdf
00258a	Adjuvant treatment HER2 positive early breast cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	docetaxel, carboplatin and trastuzumab (tch) - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/258.pdf
00722a	Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breastcancer at high risk of recurrence.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	docetaxel, carboplatin, trastuzumab and pertuzumab (tchp)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/722-docetaxel-carboplatin-trastuzumab-and-pertuzumab-tchp-therapy.pdf
00731a	Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breastcancer at high risk of recurrence.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	docetaxel, carboplatin, trastuzumab (s/c) and pertuzumab (tch(s/c)p)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/731-docetaxel-carboplatin-trastuzumab-s-c-and-pertuzumab-tch-s-c-p-therapy.pdf
00252a	Adjuvant Treatment of High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	doxorubicin and cyclophosphamide (ac 60/600) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/252.pdf
00260a	Neoadjuvant or Adjuvant Treatment of High Risk NodeNegative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	doxorubicin, cyclophosphamide followed by weekly paclitaxel therapy (ac-t)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/260-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-therapy-ac-t-.pdf
00485a	Adjuvant Treatment of High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by paclitaxel (80) 7 day therapy (dd ac-t)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/485.pdf
00485b	Neoadjuvant Treatment of High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by paclitaxel (80) 7 day therapy (dd ac-t)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/485.pdf
00278a	Adjuvant treatment of High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by paclitaxel (175) 14 day therapy (dd ac-t)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/278-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-paclitaxel-175-14-day-therapy-dd-ac-t-.pdf
00278b	Neoadjuvant treatment of High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by paclitaxel (175) 14 day therapy (dd ac-t)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/278-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-paclitaxel-175-14-day-therapy-dd-ac-t-.pdf
00432a	Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	doxorubicin, cyclophosphamide (ac 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/432-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-ac-th-.pdf
00432b	Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer..	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	doxorubicin, cyclophosphamide (ac 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/432-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-ac-th-.pdf
00433a	Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (dd ac-th)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/433-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-dd-ac-th-.pdf
00433b	Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (dd ac-th)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/433-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-dd-ac-th-.pdf
00316a	Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by paclitaxel (175) 14 day and trastuzumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/316-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-paclitaxel-175-14-day-and-trastuzumab-therapy-dd-ac-th-.pdf
00316b	Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by paclitaxel (175) 14 day and trastuzumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/316-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-paclitaxel-175-14-day-and-trastuzumab-therapy-dd-ac-th-.pdf
00262a	Adjuvant treatment for operable breast carcinoma.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	epirubicin 90 and cyclophosphamide (ec90)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/262.pdf
00376a	Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	exemestane	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf
00376b	Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	exemestane	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf
00265a	Neoadjuvant treatment for breast carcinoma.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	5-fluorouracil, epirubicin 100 and cyclophosphamide (fec 100)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/265.pdf
00265b	Adjuvant treatment for breast carcinoma.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	5-fluorouracil, epirubicin 100 and cyclophosphamide (fec 100)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/265.pdf
00371a	Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	letrozole	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf
00371b	"Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.
Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years."	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	letrozole	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf
00371d	Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	letrozole	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf
00720a	Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	neratinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf
00512a	Adjuvant Treatment of HER2 positive, Node-Negative Breast Cancer of tumor size ≤3cm.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	paclitaxel (80) and trastuzumab therapy - 7 day (12 weeks)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/512-paclitaxel-80-and-trastuzumab-therapy-%E2%80%93-7-day-12-weeks-.pdf
00785a	Pertuzumab/ trastuzumab (Phesgo®) for the maintenance treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	pertuzumab and trastuzumab (phesgo®) maintenance	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/785-pertuzumab-and-trastuzumab-phesgo-maintenance-therapy.pdf
00789a	Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	docetaxel, carboplatin and pertuzumab/trastuzumab (phesgo®)(tchp)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/789-docetaxel-carboplatin-and-pertuzumab-trastuzumab-phesgo-tchp-therapy.pdf
00790a	Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	pertuzumab/trastuzumab (phesgo®), paclitaxel and carboplatin therapy (train - 2)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/790-pertuzumab-trastuzumab-phesgo-paclitaxel-and-carboplatin-therapy-train-2-.pdf
00796a	Pertuzumab/ trastuzumab (Phesgo®)  is indicated in combination with DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	pertuzumab and trastuzumab (phesgo®) and docetaxel therapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/796-pertuzumab-and-trastuzumab-phesgo-and-docetaxel-therapy-21-day-cycle.pdf
00797a	Pertuzumab/trastuzumab (Phesgo®)  is indicated in combination with PACLitaxel  in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	pertuzumab and trastuzumab (phesgo®) and paclitaxel therapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/797-pertuzumab-trastuzumab-phesgo-and-weekly-paclitaxel-therapy-21-day-cycle.pdf
00350a	Pertuzumab in combination with trastuzumab andchemotherapy for the neoadjuvant treatment of adultpatients with HER2-positive, locally advanced,inflammatory, or early stage breast cancer at high risk ofrecurrence.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	pertuzumab and trastuzumab and chemotherapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350 pertuzumab and trastuzumab and chemotherapy.pdf
00350b	Pertuzumab in combination with trastuzumab andchemotherapy for the adjuvant treatment of adultpatients with HER2-positive breast cancer at high risk ofrecurrence.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	pertuzumab and trastuzumab and chemotherapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350 pertuzumab and trastuzumab and chemotherapy.pdf
00253a	Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	tamoxifen	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf
00200b	HER2 positive early breast cancer (EBC).	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	trastuzumab (iv) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf
00285a	Following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	trastuzumab subcutaneous 21 days - early breast cancer	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf
00285b	Following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	trastuzumab subcutaneous 21 days - early breast cancer	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf
00285c	In combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	trastuzumab subcutaneous 21 days - early breast cancer	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf
00285d	In combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours &gt; 2 cm in diameter.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	trastuzumab subcutaneous 21 days - early breast cancer	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf
00659a	As a single agent is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	trastuzumab emtansine (kadcyla®) early breast cancer therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/659-trastuzumab-emtansine-kadcyla-early-breast-cancer-therapy-21-days.pdf
00545a	Adjuvant treatment of breast cancer in endocrine depleted pre- or post menopausal women.	oral-anti-cancer-medicines, breast, breast:Neoadjuvant / Adjuvant Treatments	zoledronic acid	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/545-zoledronic-acid-monotherapy.pdf
00254a	Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	anastrozole	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf
00688a	Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	atezolizumab and nab-paclitaxel	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/688.pdf
00212c	In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	bevacizumab 10 mg/kg - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdf
00215e	In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	bevacizumab 15 mg/kg - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf
00738a	In combination with PACLitaxel for the treatment of adult patients with triple negative or HER2-negative metastatic breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	bevacizumab 10mg/kg and paclitaxel 80mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/00738-bevacizumab-10mg-kg.pdf
00216a	Treatment of patients with locally advanced or metastatic breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	capecitabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdf
00261j	Metastatic breast carcinoma.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/carboplatin-auc4-6-monotherapy-21-days1carboplatin%20auc4-6%20monotherapy-21%20days.pdf
00251j	Metastatic breast carcinoma.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00377b	Metastatic breast carcinoma.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	cyclophosphamide (oral) methotrexate and 5-fluorouracil (cmf)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/377.pdf
00381b	Metastatic breast carcinoma.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	cyclophosphamide (iv) methotrexate and 5-fluorouracil (cmf) therapy 21 day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/381.pdf
00378b	Metastatic breast carcinoma.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	cyclophosphamide (iv) methotrexate and 5-fluorouracil (cmf) therapy 28 day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/378.pdf
00741a	For the prevention of skeletal related events in adult patients with malignancies involving bone.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	denosumab 120mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/741-densosumab-therapy.pdf
00745a	Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by weekly paclitaxel (80) and trastuzumab 21 day therapy (dd ac-th)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/745-dose-dense-doxorubicin-cyclophosphamide.pdf
00745b	Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	dose dense doxorubicin, cyclophosphamide (ac 60/600) 14 day followed by weekly paclitaxel (80) and trastuzumab 21 day therapy (dd ac-th)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/745-dose-dense-doxorubicin-cyclophosphamide.pdf
00203h	Treatment of advanced breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	docetaxel monotherapy 75mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf
00202a	Docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	docetaxel monotherapy 100mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/202.pdf
00423a	Treatment of Locally Advanced or Metastatic Breast Carcinoma.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	doxorubicin 50mg/m2/docetaxel 75mg/m2(at 50/75) therapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/423.pdf
00205a	Monotherapy for patients with metastatic breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	pegylated liposomal doxorubicin 50mg/m2 (caelyx®) 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/205-pegylated-liposomal-doxorubicin-50mg-m2-caelyx-%C2%AE-28-days-regimen.pdf
00263a	Metastatic breast carcinoma.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	epirubicin 75 + cyclophosphamide (ec75)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/263.pdf
00228a	Treatment of locally advanced or metastatic breast cancer which has progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	eribulin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/228-eribulin-monotherapy.pdf
00743a	Treatment of locally advanced or metastatic breast cancer which has progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	eribulin monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/eribulin-monotherapy-28-day743.pdf
00322a	Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	everolimus and exemestane	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdf
00376c	"Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.
Advanced breast cancer after relapse or disease porgression in women with natural or artificially induced post menopausal endocrine status."	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	exemestane	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf
00269a	Metastatic breast carcinoma.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	5-fluorouracil, epirubicin 50 and cyclophosphamide (fec50)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/269.pdf
00361a	Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	fulvestrant	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf
00361b	Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-oestrogen therapy.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	fulvestrant	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf
00430a	Treatment of locally recurrent metastatic triple negative breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	gemcitabine and carboplatin (auc2) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdf
00217a	"Treatment of adult patients with breast cancer, whose tumours overexpress HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.
Treatment of adult patients with breast cancer, whose tumours over express HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting."	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	lapatinib and capecitabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdf
00371c	"Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.
Advanced breast cancer after relapse or disease progression in women with natural or artificially induced post menopausal endocrine status."	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	letrozole	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf
00226a	Treatment of metastatic breast carcinoma (mBC) in patients who have either failed or are not candidates for standard, anthracycline-containing therapy.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	paclitaxel monotherapy 80mg/m2 day 1, 8, 15 and 22 - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/226-paclitaxel-monotherapy-80mg-m2-7day-cycle.pdf
00621b	Treatment of metastatic breast carcinoma (mBC) in patients who have either failed or are not candidates for standard, anthracycline-containing therapy.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	paclitaxel 80mg/m2 day 1, 8 and 15 monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf
00230a	Treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	nab-paclitaxel monotherapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/230-nab-paclitaxel-abraxane%C2%AE-monotherapy-%E2%80%93-21-day-cycle.pdf
00736a	Treatment of metastatic breast carcinoma (mBC) in patients who haveeither failed or are not candidates for standard, anthracycline-containing therapy.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	nab-paclitaxel weekly monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/nab-paclitaxel-weekly-monotherapy28-day.pdf
00414a	Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	palbociclib therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf
00414b	Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	palbociclib therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf
00204a	Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti HER2 therapy or chemotherapy for their metastatic disease.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	pertuzumab and trastuzumab and docetaxel therapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/204-pertuzumab-and-trastuzumab-and-docetaxel-therapy-21-day-cycle.pdf
00507a	Pertuzumab is indicated in combination with trastuzumab and PACLitaxel  in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	pertuzumab trastuzumab and weekly paclitaxeltherapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/507.pdf
00775a	Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	pertuzumab trastuzumab, paclitaxel and carbo	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/775-pertuzumab-trastuzumab-paclitaxel-and-carboplatin-therapy-train-2-.pdf
00726a	Pertuzumab in combination with trastuzumab for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	pertuzumab and trastuzumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/726-pertuzumab-trastuzumab-therapy.pdf
00526a	­­­­Pertuzumab in combination with trastuzumab and vinorelbine for the treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	pertuzumab trastuzumab and vinorelbine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/526-pertuzumab-trastuzumab-and-vinorelbine.pdf
00525a	Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	ribociclib therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf
00525b	Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy.In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	ribociclib therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf
00605a	Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	talazoparib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf
00253b	Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	tamoxifen	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf
00201a	The treatment of patients with HER2 positive metastatic breast cancer (MBC).	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	trastuzumab (iv) monotherapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/201.pdf
00200a	HER2 positive metastatic breast cancer (MBC).	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	trastuzumab (iv) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf
00272a	As monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	trastuzumab subcutaneous - 21 days - metastatic breast carcinoma	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf
00272b	In combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	trastuzumab subcutaneous - 21 days - metastatic breast carcinoma	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf
00272c	In combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	trastuzumab subcutaneous - 21 days - metastatic breast carcinoma	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf
00272d	In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	trastuzumab subcutaneous - 21 days - metastatic breast carcinoma	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf
00206a	Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.Patients should have either:.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	trastuzumab emtansine (kadcyla®) - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/206.pdf
00232a	Advanced breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	intravenous vinorelbine therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/232-intravenous-vinorelbine-therapy-21-days.pdf
00259a	Advanced breast cancer.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	oral vinorelbine monotherapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/259.pdf
00723a	Prevention of skeletal related events in malignancies involving bone metastases.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	zoledronic acid therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/zoledronic-acid-28days-v1-723.pdf
00724a	Prevention of skeletal related events in malignancies involving bone metastases.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	zoledronic acid therapy - 3 monthly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/zoledronic-acid-3-monthly-v1-724.pdf
00725a	Prevention of skeletal related events in malignancies involving bone metastases.	genitourinary:Prostate Chemotherapy Regimens, breast, breast:Locally Advanced / Metastatic Regimens, sarcoma, oral-anti-cancer-medicines, genitourinary	zoledronic acid therapy - 6 monthly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/zoledronic-acid-6-monthly-v1-725.pdf
00717a	Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	car-t-therapy	axicabtagene ciloleucel (yescarta®) (car-t) dlbcl and pmbcl	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/717-axicabtagene-dlbcl-and-pmbcl.pdf
00608a	Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy with axicabtagene ciloleucel (Yescarta®) in adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	car-t-therapy	fludarabine & cyclophosphamide lymphodepletion for axicabtagene ciloleucel (yescarta®)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/608-fludarabine-cyclophosphamide-lymphodepletion-yescarta-.pdf
00606a	Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy.	car-t-therapy	fludarabine & cyclophosphamide lymphodepletion for tisagenlecleucel (kymriah®) dlbcl	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/606 .pdf
00607a	Lymphodepleting chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients aged 18-25 years with B-cell ALL that is refractory, in relapse post-transplant or in second or later relapse.	car-t-therapy	fludarabine & cyclophosphamide lymphodepletion for tisagenlecleucel (kymriah®) b-cell all	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/607.pdf
00687a	Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	car-t-therapy	tisagenlecleucel (kymriah®) (car-t) dlbcl	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/687.pdf
00686a	Treatment of young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.	car-t-therapy	tisagenlecleucel (kymriah®) (car-t) b-all	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/686.pdf
00238a	Aflibercept is indicated as second line therapy in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	aflibercept and folfiri therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/238-aflibercept-and-folfiri-therapy-14-days.pdf
00212a	In combination with fluoropyrimidine-based chemotherapy for treatment of adult patients with metastatic carcinoma of the colon or rectum.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	bevacizumab 10 mg/kg - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/212.pdf
00214a	In combination with fluoropyrimidine-based chemotherapy for treatment of adult patients with metastatic carcinoma of the colon or rectum.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	bevacizumab 7.5 mg/kg - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/214.pdf
00215d	In combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	bevacizumab 15 mg/kg - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/215-bevacizumab-15mg-kg-therapy.pdf
00449a	Treatment of adult patients with metastatic carcinoma of the colon or rectum.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	bevacizumab 5mg/kg and folfiri therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/449.pdf
00446a	Treatment of adult patients with metastatic carcinoma of the colon or rectum.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	bevacizumab 5mg/kg and modified folfox - 6 therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/446.pdf
00783a	Treatment of metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	bevacizumab 5mg/kg and folfoxiri - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/783-bevacizumab-and-folfoxiri.pdf
00623a	Treatment of metastatic or unresectable colorectal cancer in patients not suitable for combination chemotherapy with irinotecan or oxaliplatin.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	bevacizumab 7.5mg/kg and capecitabine 1250mg/m2 therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/00623a.pdf
00216b	Treatment of metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/216-capecitabine-monotherapy.pdf
00216c	Adjuvant treatment of patients following surgery of stage III colon cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/216-capecitabine-monotherapy.pdf
00216d	Adjuvant treatment of patients following surgery of stage II colon cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/216-capecitabine-monotherapy.pdf
00216e	Adjuvant treatment of patients with metastatic colorectal cancer following complete resection.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/216-capecitabine-monotherapy.pdf
00586a	Locally advanced rectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine 825mg/m2 and rt - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/586-capecitabine-825mg-m2-and-rt%E2%80%937-day.pdf
00523a	Locally advanced pancreatic cancer after induction chemotherapy.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine and rt - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/523-capecitabine-and-rt%E2%80%937-day.pdf
00505a	Treatment of patients with locally advanced or metastatic neuroendocrine tumours of the pancreas.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine and temozolomide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/505.pdf
00321a	Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of the primary tumour.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine/oxaliplatin (xelox)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/321.pdf
00321b	Treatment of advanced or metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine/oxaliplatin (xelox)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/321.pdf
00321c	Adjuvant Stage II/III gastric adenocarcinoma post D2 gastrectomy.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	capecitabine/oxaliplatin (xelox)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/321.pdf
00422a	Preoperative chemoradiation treatment of oesophageal and gastro-oesophageal junction carcinomas.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	carboplatin (auc 2) weekly and paclitaxel (50mg/m2) weekly with radiotherapy (rt) - 5 weeks	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/422.pdf
00207a	Treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC).	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cetuximab therapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/207.pdf
00732a	As monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC) in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cetuximab therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/732-cetuximab-therapy-14-days.pdf
00330a	Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cetuximab (7days) and irinotecan (14 days )	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/330-cetuximab-7days-and-irinotecan-14-days-therapy.pdf
00331a	Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cetuximab (14 days) and irinotecan (14 days )	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/331-cetuximab-14-days-and-irinotecan-14-days-therapy-.pdf
00692a	Treatment of patients with RAS wild type metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cetuximab and folfox - 4	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/692-cetuximab-and-folfox4.pdf
00585a	Treatment of patients with RAS wild type metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cetuximab (14 days) and folfiri (14 days)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/585.pdf
00733a	Treatment of patients with KRAS wild type metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cetuximab and folfox - 6 (modified)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/733-cetuximab-and-folfox-6-modified-therapy.pdf
00473a	Adjuvant treatment of adult patients with resected gastric cancer stage IIA or higher and no distant metastases.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cisplatin and capecitabine adjuvant chemoradiation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/473.pdf
00460a	Locally advanced squamous or adenocarcinoma of the oesophagus not suitable for surgery.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cisplatin 75mg/m2 and 5-fluorouracil chemoradiation therapy-herskovic regimen	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/460.pdf
00594a	Treatment of anal canal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cisplatin, 5-fluorouracil and radiation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/594.pdf
00235a	"Treatment of advanced gastric cancer when given in combination with cisplatin.
Treatment of advanced gastric cancer when given in combination with CISplatin."	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	cisplatin and teysuno® - 28 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/235-cisplatin-and-teysuno%C2%AE-28-day-cycle.pdf
00203d	Advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who have progressed during or within 6 months after treatment with a platinum-fluoropyrimidine combination.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	docetaxel monotherapy 75mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf
00386a	Treatment of unresectable or metastatic hepatocellular carcinoma not suitable for treatment with regional therapies.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	doxorubicin 60mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/386.pdf
00240a	Metastatic or locally advanced (unresectable) gastric adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and 5-fu (ecf)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/240-epirubicin-cisplatin-and-5-fu-ecf-therapy.pdf
00240b	Metastatic or locally advanced (unresectable) esophagogastric junction adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and 5-fu (ecf)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/240-epirubicin-cisplatin-and-5-fu-ecf-therapy.pdf
00240c	Metastatic or locally advanced (unresectable) oesophageal  adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and 5-fu (ecf)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/240-epirubicin-cisplatin-and-5-fu-ecf-therapy.pdf
00240d	Perioperative treatment of resectable gastric adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and 5-fu (ecf)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/240-epirubicin-cisplatin-and-5-fu-ecf-therapy.pdf
00240e	Perioperative treatment of resectable gastroesophageal junction adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and 5-fu (ecf)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/240-epirubicin-cisplatin-and-5-fu-ecf-therapy.pdf
00240f	Perioperative treatment of resectable lower oesophagus adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and 5-fu (ecf)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/240-epirubicin-cisplatin-and-5-fu-ecf-therapy.pdf
00380a	Perioperative treatment of resectable gastric adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and capecitabine (ecx)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/380.pdf
00380b	"Perioperative treatment of resectable gastrioesophageal junction adenocarcainoma.
Perioperative treatment of resectable gastroesophageal junction adenocarcinoma."	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and capecitabine (ecx)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/380.pdf
00380c	Perioperative treatment of resectable lower oesophagus adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and capecitabine (ecx)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/380.pdf
00380d	Palliative therapy for metastatic or locally advanced gastric adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and capecitabine (ecx)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/380.pdf
00380e	"Palliative therapy for metastatic or locally advanced oesphagogastric adenoccarcinoma.
Palliative therapy for metastatic or locally advanced oesphagogastric adenocarcinoma."	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, cisplatin and capecitabine (ecx)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/380.pdf
00429a	Locally advanced or metastatic gastric carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin oxaliplatin and 5-fu (eof) - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/429.pdf
00429b	Locally advanced or metastatic oesophageal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin oxaliplatin and 5-fu (eof) - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/429.pdf
00429c	Locally advanced or metastatic gastroesophageal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin oxaliplatin and 5-fu (eof) - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/429.pdf
00239a	Locally advanced or metastatic gastric carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, oxaliplatin and capecitabine (eox)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/239.pdf
00239b	Locally advanced or metastatic oesophageal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, oxaliplatin and capecitabine (eox)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/239.pdf
00239c	Locally advanced or metastatic gastroesophageal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	epirubicin, oxaliplatin and capecitabine (eox)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/239.pdf
00320b	Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	everolimus	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/320-everolimus-monotherapy.pdf
00320c	The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	everolimus	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/320-everolimus-monotherapy.pdf
00344a	Treatment of locally advanced (≥T2) and/or nodal positive (N+) resectable gastric adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	flot therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/344.pdf
00344b	Treatment of locally advanced ((≥T2) and/or nodal positive (N+) resectable adenocarcinoma of the oesophagogastreal junction.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	flot therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/344.pdf
00486a	Adjuvant treatment of stage II or III colon cancer after complete resection of primary tumour.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	flox	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/486.pdf
00227a	Treatment of patients with advanced colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfiri therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/227-folfiri-therapy-14-day.pdf
00227b	Treatment of patients with metastatic oesophageal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfiri therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/227-folfiri-therapy-14-day.pdf
00227c	Second line treatment of patients with locally advanced metastatic pancreatic carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfiri therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/227-folfiri-therapy-14-day.pdf
00328a	Treatment of patients with RAS wild type metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfiri (14 days) and cetuximab (7 days)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/328.pdf
00210a	Adjuvant treatment of stage II and stage III colon cancer after complete resection of primary tumour.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfox - 4 therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/210.pdf
00210b	Metastatic colorectal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfox - 4 therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/210.pdf
00209a	Adjuvant treatment of stage II or III colon cancer after complete resection of primary tumour.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfox - 6 modified therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/209.pdf
00209b	Metastatic colorectal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfox - 6 modified therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/209.pdf
00209c	Advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfox - 6 modified therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/209.pdf
00509a	Definitive squamous cell carcinoma (SCC) or adenocarcinoma of the oesophagus in combination in patients for whom a CISplatin based regimen is contraindicated.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfox - 6 modified chemoradiation therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/509.pdf
00555a	Treatment of  metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfoxiri	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/555.pdf
00329a	Metastatic pancreatic cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfirinox	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/329.pdf
00515a	Adjuvant treatment of pancreatic ductal adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	modified folfirinox	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/515.pdf
00691a	Neoadjuvant chemotherapy for locally advanced rectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	folfirinox therapy - (rectal carcinoma)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/folfirinox-rectal-carcinoma-v1-691.pdf
00660a	Adjuvant treatment of colorectal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	5-fluorouracil and folinic acid therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/660-5-fu-and-folinic-acid-therapy-14-day.pdf
00660b	Locally advanced, locally recurrent or metastatic colorectal adenocarcinoma not curable with surgery or radiation.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	5-fluorouracil and folinic acid therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/660-5-fu-and-folinic-acid-therapy-14-day.pdf
00451a	Treatment of anal canal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	5-fluorouracil (4 day) and mitomycin chemoradiation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/451-5-fluorouracil-4-day-and-mitomycin-chemoradiation-therapy.pdf
00421a	Treatment of locally advanced rectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	5-fluorouracil 225mg/m2/day and radiotherapy (rt)-continuous infusion (7day)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/421 5-fu.pdf
00284a	Adjuvant chemotherapy for pancreatic adenocarcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine 1000mg/m2 monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/284-gemcitabine-1000mg-m2-monotherapy-28-day.pdf
00283a	Treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine 1000mg/m2 monotherapy - 56 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/283.pdf
00522a	Resectable Adenocarcinoma of the head of Pancreas.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine (400mg/m2) and rt	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/522-gemcitabine-400mg-m2-and-rt-therapy.pdf
00559a	Treatment of patients with localized unresectable adenocarcinoma of the pancreas.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine (600mg/m2) and rt therapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/gemcitabine-600mg-m2-and-rt-therapy-%E2%80%93-7day.pdf
00521a	Non-metastatic, locally advanced pancreatic cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine (1000mg/m2) and rt	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/521-gemcitabine-1000mg-m2-and-rt-therapy.pdf
00384a	Locally advanced or metastatic pancreatic carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine (1000mg/m2) and capecitabine (650mg/m2) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/384-gemcitabine-1000mg-m2-and-capecitabine-650mg-m2-therapy-21-day.pdf
00384b	"Locally advanced biliary tree carcinoma.
Locally advanced bilary tree carcinoma."	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine (1000mg/m2) and capecitabine (650mg/m2) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/384-gemcitabine-1000mg-m2-and-capecitabine-650mg-m2-therapy-21-day.pdf
00524a	Adjuvant treatment of pancreatic adenocarcinoma after macroscopic complete resection.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine (1000mg/m2) and capecitabine (830mg/m2) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/524.pdf
00383a	Locally advanced or metastatic pancreatic carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine (1000mg/m2) and cisplatin (25mg/m2)therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/383-gemcitabine-1000mg-m2-and-cisplatin-25mg-m2-therapy-21-day.pdf
00383b	Locally advanced or metastatic biliary tree carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	gemcitabine (1000mg/m2) and cisplatin (25mg/m2)therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/383-gemcitabine-1000mg-m2-and-cisplatin-25mg-m2-therapy-21-day.pdf
00213a	Treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	irinotecan monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/213-irinotecan-monotherapy-21days.pdf
00654a	Second line therapy for advanced gastric cancer refractory to treatment with fluoropyrimidine plus platinum.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	irinotecan 150mg/m2 monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/654.pdf
00644a	As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	lenvatinib - hcc therapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/644-lenvatinib-hcc-therapy.pdf
00727	Treatment of anal canal carcinoma.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	mitomycin and capecitabine chemoradiation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/727-mitomycin-and-capecitabine-chemoradiation-therapy.pdf
00256a	First-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	nab-paclitaxel and gemcitabine - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/256.pdf
00621a	Second line chemotherapy for advanced or recurrent gastric cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	paclitaxel 80mg/m2 day 1, 8 and 15 monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf
00225c	Treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) As monotherapy after failure of fluorpyridine, oxaliplatin, and irinotecan containing chemotherapy regimens.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	panitumumab 6mg/kg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/225.pdf
00448a	First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC).	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	panitumumab 6mg/kg and folfiri therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/448 panitumumab-6mg-kg-and-folfiri-therapy-14-day.pdf
00448b	Second line treatment of adult patients with wild-type RAS mCRC who have received first-line fluorpyridine–based chemotherapy (excluding irinotecan).	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	panitumumab 6mg/kg and folfiri therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/448 panitumumab-6mg-kg-and-folfiri-therapy-14-day.pdf
00447a	First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC).	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	panitumumab 6mg/kg and modified folfox - 6 therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/447.pdf
00428a	Treatment of metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	quasar (modified) flu fluorouracil (370mg/m2) andfolinic acid (50mg) weekly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/428-qqquasar-modified-flu-fluorouracil-370mg-m2-and-3-and-folinic-acid-50mg-weekly.pdf
00428b	Adjuvant treatment of colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	quasar (modified) flu fluorouracil (370mg/m2) andfolinic acid (50mg) weekly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/428-qqquasar-modified-flu-fluorouracil-370mg-m2-and-3-and-folinic-acid-50mg-weekly.pdf
00244a	Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	regorafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/244.pdf
00427a	Treatment of metastatic colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	roswell park modified (fluorouracil 500mg/m2 and folinic acid 50mg weekly x 6) regimen	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/427.pdf
00427b	Adjuvant treatment of colorectal cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	roswell park modified (fluorouracil 500mg/m2 and folinic acid 50mg weekly x 6) regimen	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/427.pdf
00294a	Treatment of hepatocellular carcinoma (HCC).	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	sorafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/294-sorafenib-therapy.pdf
00502a	Treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	trastuzumab 5 fluorouracil and cisplatin therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/502trastuzumab-5-fluorouracil-and-cisplatin-therapy-21.pdf
00704a	Treatment of adult patients with HER2 positive metastatic gastric or gastroesophageal junction cancer.	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	trastuzumab and folfox - 6 modified therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/trastuzumab-with-folfox6-modified-v1-final.pdf
00382a	"Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
Treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine, oxaliplatin and irinotecan based therapies, anti-VEGF and anti-EGFR agents."	oral-anti-cancer-medicines, gastrointestinal, neuroendocrine	trifluridine and tipiracil (lonsurf®) therapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/382.pdf
00544b	Treatment of adult patients with locally advanced or metastaticurothelial carcinoma (UC) after prior platinum-containingchemotherapy.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	atezolizumab 1200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf
00544c	Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	atezolizumab 1200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf
00593b	Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	atezolizumab 1680mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf
00593c	Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	atezolizumab 1680mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf
00535	First-line maintenance treatment of adult patients with locally advancedor metastatic urothelial carcinoma (UC) who are progression-free following platinum based chemotherapy.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	avelumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/535-avelumab-monotherapy.pdf
00385b	Chemoradiation treatment for locally advanced bladder cancer.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	cisplatin 40mg/m2 weekly with radiotherapy (rt)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/385-cisplatin-40mg-m2-weekly-with-radiotherapy-rt-.pdf
00337a	Neoadjuvant treatment of muscle invasive transitional cell carcinoma (TCC) of the urothelium.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	cisplatin, methotrexate and vinblastine (cmv)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/337-cisplatin-methotrexate-and-vinblastine-cmv-therapy.pdf
00450a	Treatment of muscle invasive bladder cancer in patients.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	5-fluorouracil (5 day) and mitomycin chemoradiation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/450-5-fluorouracil-5-day-and-mitomycin-chemoradiation-therapy.pdf
00622a	Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium in patients with impaired renal function.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	gemcitabine (1000mg/m2) and cisplatin (35mg/m2) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/622.pdf
00628a	Adjuvant treatment of upper tract urothelial carcinoma.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	gemcitabine (1000mg/m2) and cisplatin (70mg/m2)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/628.pdf
00310a	Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium where cisplatin is contraindicated.*.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	gemcitabine (1000mg/m2) and carboplatin (auc5) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf
00282a	Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	gemcitabine (1000mg/m2) and cisplatin (70mg/m2) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/282-gemcitabine-1000mg-m2-and-cisplatin-70mg-m2-therapy-28-day.pdf
00333a	Locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	methotrexate, vinblastine, doxorubicin, cisplatin (mvac) therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/333-methotrexate-vinblastine-doxorubicin-cisplatin-mvac-therapy-14-days.pdf
00338a	Neoadjuvant treatment of muscle invasive transitional cell carcinoma (TCC) of the urothelium.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	methotrexate, vinblastine, doxorubicin, cisplatin (mvac) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/338-methotrexate-vinblastine-doxorubicin-cisplatin-mvac-therapy-28-days.pdf
00338b	Adjuvant treatment of muscle invasive TCC of the urothelium.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	methotrexate, vinblastine, doxorubicin, cisplatin (mvac) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/338-methotrexate-vinblastine-doxorubicin-cisplatin-mvac-therapy-28-days.pdf
00338c	Locally advanced or metastatic TCC of the urothelium.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	methotrexate, vinblastine, doxorubicin, cisplatin (mvac) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/338-methotrexate-vinblastine-doxorubicin-cisplatin-mvac-therapy-28-days.pdf
00226e	Second line chemotherapy for metastatic bladder cancerii.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	paclitaxel monotherapy 80mg/m2 day 1, 8, 15 and 22 - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/226-paclitaxel-monotherapy-80mg-m2-7day-cycle.pdf
00621e	Second line chemotherapy for metastatic bladder cancer.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	paclitaxel 80mg/m2 day 1, 8 and 15 monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf
00455e	As monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	pembrolizumab 200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab 200mg monotherapy 455 .pdf
00455f	As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) ≥10.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	pembrolizumab 200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab 200mg monotherapy 455 .pdf
00558e	As monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	pembrolizumab 400mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/558-pembrolizumab-400-mg-monotherapy.pdf
00558f	As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) ≥10.	genitourinary, genitourinary:Bladder Cancer Chemotherapy Regimens	pembrolizumab 400mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/558-pembrolizumab-400-mg-monotherapy.pdf
00300a	Adjuvant treatment of high risk (vascular invasion carcinoma) stage 1 nonseminoma germ cell tumour.	genitourinary:Germ Cell Chemotherapy Regimens, gynaecology:Ovarian Chemotherapy Regimens, genitourinary, gynaecology	bleomycin, etoposide and cisplatin (bep)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/300-bleomycin-etoposide-and-cisplatin-bep-therapy.pdf
00300b	Metastatic germ cell tumours of the testis.	genitourinary:Germ Cell Chemotherapy Regimens, gynaecology:Ovarian Chemotherapy Regimens, genitourinary, gynaecology	bleomycin, etoposide and cisplatin (bep)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/300-bleomycin-etoposide-and-cisplatin-bep-therapy.pdf
00300c	Advanced stage or metastatic germ cell tumours (dysgermimoma) of the ovaries.	genitourinary:Germ Cell Chemotherapy Regimens, gynaecology:Ovarian Chemotherapy Regimens, genitourinary, gynaecology	bleomycin, etoposide and cisplatin (bep)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/300-bleomycin-etoposide-and-cisplatin-bep-therapy.pdf
00300d	Extra-gonadal germ cell tumours.	genitourinary:Germ Cell Chemotherapy Regimens, gynaecology:Ovarian Chemotherapy Regimens, genitourinary, gynaecology	bleomycin, etoposide and cisplatin (bep)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/300-bleomycin-etoposide-and-cisplatin-bep-therapy.pdf
00453a	Treatment of metastatic relapsed/refractory germ cell tumours.	genitourinary:Germ Cell Chemotherapy Regimens, gynaecology:Ovarian Chemotherapy Regimens, genitourinary, gynaecology	carboplatin (auc7) and etoposide- autologous conditioning germ cell tumour regimen	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/453-carboplatin-auc7-and-etoposide-autologous-conditioning-germ-cell-tumour-regimen.pdf
00301a	"Treatment of good prognosis (IGCCCG criteria) metastatic germ cell tumours (both non-seminoma and seminoma).
Treatment of good prognosis (IGCCCG criteria) metastatic germ cell tumours (both non-seminoma and seminoma).."	genitourinary:Germ Cell Chemotherapy Regimens, gynaecology:Ovarian Chemotherapy Regimens, genitourinary, gynaecology	etoposide and cisplatin 20mg/m2 (ep) 5 day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/301-etoposide-and-cisplatin-20mg-m2-ep-therapy.pdf
00437a	Treatment of metastatic relapsed/refractory germ cell tumours.	genitourinary:Germ Cell Chemotherapy Regimens, gynaecology:Ovarian Chemotherapy Regimens, genitourinary, gynaecology	tice - autologous conditioning germ cell tumour regimen	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/437-tice-autologous-conditioning-germ-cell-tumour-regimen.pdf
00103a	"Treatment of mCRPC which has progressed on or after a docetaxel-based chemotherapy regimen.
Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen."	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	abiraterone and prednisolone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/103-abiraterone-and-prednisolone-therapy.pdf
00103b	Treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	abiraterone and prednisolone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/103-abiraterone-and-prednisolone-therapy.pdf
00577a	Abiraterone is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	abiraterone 1000mg and prednisolone 5mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/577.pdf
00574a	Apalutamide is indicated for the treatment of adult men with nonmetastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	apalutamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/574.pdf
00482	Treatment of advanced prostate cancer in combination with luteinizing-hormone releasing hormone (LHRH) analogue therapy or surgical castration.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	bicalutamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/482-bicalutamide-therapy.pdf
00101a	Cabazitaxel is indicated in combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	cabazitaxel and prednisolone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/cabazitaxelprotocol.pdf
00693a	Treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	darolutamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/693.pdf
00481a	Treatment of adult male patients with advanced hormone-dependent prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	degarelix	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/481-degarelix-therapy.pdf
00313a	In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	docetaxel monotherapy 50mg/m2 - 14 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/313-docetaxel-monotherapy-50mg-m2-%E2%80%93-14-day-cycle.pdf
00203b	First line in high risk non metastic castration sensitive prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	docetaxel monotherapy 75mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf
00203c	First line in metastatic castration sensitive prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	docetaxel monotherapy 75mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf
00546a	In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	docetaxel 75 mg/m2 - prednisolone combination	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/546-docetaxel-75mg-m2-%E2%80%93prednisolone-combination-therapy.pdf
00233a	"Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after DOCEtaxel therapy."	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	enzalutamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/233-enzalutamide-monotherapy.pdf
00233b	Treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	enzalutamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/233-enzalutamide-monotherapy.pdf
00233c	The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	enzalutamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/233-enzalutamide-monotherapy.pdf
00478a	Treatment of locally advanced or metastatic hormone sensitive prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	goserelin 3.6mg therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/478-goserelin-3-6mg-therapy-28-day.pdf
00477a	Treatment of locally advanced or metastatic hormone sensitive prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	goserelin 10.8mg therapy - 12week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/477-goserelin-10-8mg-therapy-12week.pdf
00494a	Management of prostatic carcinoma for which a suppression of testosterone is indicated.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 3.75mg therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/494-leuprorelin-3-75mg-therapy-28-day.pdf
00490a	Treatment of hormone dependent advanced prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 7.5mg therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/490-leuprorelin-7-5mg-therapy-28-day.pdf
00490b	Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 7.5mg therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/490-leuprorelin-7-5mg-therapy-28-day.pdf
00492a	Management of prostatic carcinoma for which a suppression of testosterone is indicated.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 11.25mg therapy - 12 week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/492-leuprorelin-11-25mg-therapy-12-week.pdf
00479a	Treatment of hormone dependent advanced prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 22.5mg therapy - 12 week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/479-leuprorelin-22-5mg-therapy-12-week.pdf
00479b	Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 22.5mg therapy - 12 week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/479-leuprorelin-22-5mg-therapy-12-week.pdf
00493a	Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 30mg - 24 week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/493-leuprorelin-30mg-24-week.pdf
00491a	Treatment of hormone dependent advanced prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 45mg therapy - 24 week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/491-leuprorelin-45mg-therapy-24-week.pdf
00491b	Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	leuprorelin 45mg therapy - 24 week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/491-leuprorelin-45mg-therapy-24-week.pdf
00257a	As monotherapy or in combination with LHRH analogues for the treatment of adults with progressive castration-resistant metastatic prostate cancer (mCRPC, symptomatic bone metastases and no extensive visceral metastases after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available licensed systemic mCRPC treatment.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	radium 223	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/257-radium-223-therapy1.pdf
00489a	Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	triptorelin 3mg therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/489-triptorelin-3mg-therapy-28-day.pdf
00480a	Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	triptorelin 11.25mg therapy - 12 week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/480-triptorelin-11-25mg-therapy-12-week.pdf
00488a	Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Prostate Chemotherapy Regimens	triptorelin 22.5mg therapy - 24 week	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/488-triptorelin-22-6mg-therapy-24-week.pdf
00104a	"Treatment of adult patients with advanced RCC after failure, on a previous line of therapy, i.e. treatment with SUNItinib, or a cytokine.
Treatment of adult patients with advanced renal cell carcinoma (RCC) after failure, on a previous line of therapy, i.e. treatment with SUNItinib, or a cytokine."	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	axitinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/axitinib104.pdf
00592a	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	atezolizumab 840mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf
00592b	Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	atezolizumab 840mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf
00592c	Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	atezolizumab 840mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf
00212d	In combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	bevacizumab 10 mg/kg - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/212.pdf
00518a	Treatment of advanced renal cell carcinoma (RCC) in adults following prior VEGF targeted therapy.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	cabozantinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/518 cabozantinib therapy.pdf
00320a	Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	everolimus	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/320-everolimus-therapy.pdf
00583a	Pembrolizumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	pembrolizumab 200mg and axitinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/583.pdf
00483b	As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	nivolumab 240mg monotherapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/483-nivolumab-240mg-monotherapy.pdf
00484b	As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	nivolumab 480mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf
00551a	Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	nivolumab 3mg/kg with ipilimumab 1mg/kg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf
00445a	First line treatment of advanced Renal Cell Carcinoma (RCC) in adults and for patients who have received prior cytokine therapy for advanced disease.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	pazopanib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/445-pazopanib-therapy.pdf
00294b	Treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	sorafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/294-sorafenib-therapy.pdf
00325b	Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	sunitinib 50mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/325-sunitnib-50mg-therapy.pdf
00719b	"Treatment of clear-cell type metastatic renal cell carcinoma (MRCC).
Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults."	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	sunitinib 50mg (21 days)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/sunitinib-50mg-therapy1.pdf
00326a	First-line treatment of adult patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	temsirolimus	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/326-temsirolimus-monotherapy.pdf
00564a	Tivozanib for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.	oral-anti-cancer-medicines, genitourinary, genitourinary:Renal Chemotherapy Regimens	tivozanib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/564-tivozanib-therapy.pdf
00419b	Chemoradiation treatment in locally advanced cervical cancer when CISplatin is contraindicated or not tolerated.	gynaecology:Regimens, gynaecology	carboplatin (auc 2) weekly with radiotherapy (rt)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/419-carboplatin-auc-2-weekly-with-radiotherapy-rt-.pdf
00385a	Chemoradiation treatment for locally advanced (stage IIB to IVA) cervical squamous cell carcinoma (SCC).	gynaecology:Regimens, gynaecology	cisplatin 40mg/m2 weekly with radiotherapy (rt)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/385-cisplatin-40mg-m2-weekly-with-radiotherapy-rt-.pdf
00247a	Alternative treatment of low risk gestational trophoblastic disease (GTD) (risk score ≤ 6).	gynaecology	dactinomycin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/247-dactinomycin-therapy.pdf
00248a	Treatment of high risk gestational trophoblastic neoplasia (GTN) (FIGO score ≥7).	gynaecology	ema/co therapy (etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/248-ema-co-therapy-etoposide-methotrexate-dactinomycin-cyclophosphamide-vincristine-.pdf
00248b	Treatment of patients with low risk GTN who have not responded or have relapsed from single agent chemotherapy (methotrexate or actinomycin D).	gynaecology	ema/co therapy (etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/248-ema-co-therapy-etoposide-methotrexate-dactinomycin-cyclophosphamide-vincristine-.pdf
00267a	Emergency treatment of women with Gestational Trophoblastic Neoplasia (GTN) who are acutely unwell from liver or CNS disease and particularly those at risk of respiratory failure.	gynaecology	two day etoposide cisplatin (ep)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/267-two-day-etoposide-cisplatin-ep-therapy.pdf
00267b	Hepatic Metastases.Women with GTN who are acutely unwell from liver disease.	gynaecology	two day etoposide cisplatin (ep)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/267-two-day-etoposide-cisplatin-ep-therapy.pdf
00267c	Cerebral Metastases.Women with GTN who are acutely unwell from cerebral metastases.	gynaecology	two day etoposide cisplatin (ep)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/267-two-day-etoposide-cisplatin-ep-therapy.pdf
00264a	Treatment of women with high-risk Gestational Trophoblastic Neoplasia (GTN) who have not responded or have relapsed from treatment with EMA/CO.	gynaecology	ema/ep therapy (etoposide methotrexate dactinomycin/etoposide cisplatin)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/264-ep-ema-therapy-etoposide-cisplatin-etoposide-methotrexate-dactinomycin-.pdf
00264b	GTN and hepatic metastases. Women with GTN and hepatic metastases at presentation.	gynaecology	ema/ep therapy (etoposide methotrexate dactinomycin/etoposide cisplatin)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/264-ep-ema-therapy-etoposide-cisplatin-etoposide-methotrexate-dactinomycin-.pdf
00249a	Central nervous system (CNS) prophylaxis in patients with high risk gestational trophoblastic neoplasia (GTN).	gynaecology	intrathecal methotrexate for cns prophylaxis in gtn	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/249-intrathecal-methotrexate-for-cns-prophylaxis-in-gtn.pdf
00249b	Central nervous system (CNS) prophylaxis in patients with low risk gestational trophoblastic neoplasia (GTN) with lung metastases.	gynaecology	intrathecal methotrexate for cns prophylaxis in gtn	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/249-intrathecal-methotrexate-for-cns-prophylaxis-in-gtn.pdf
00246a	Treatment of low risk gestational trophoblastic disease (GTD) (FIGO score ≤ 6).	gynaecology	methotrexate 8 day charing cross regimen	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/246-methotrexate-8-day-charing-cross-regimen.pdf
00266a	Treatment of women with high-risk Gestational Trophoblastic Neoplasia (GTN) who have not responded or have relapsed from treatment with EMA/CO.	gynaecology	paclitaxel/etoposide alternating with paclitaxel/cisplatin (te/tp)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/266-paclitaxel-cisplatin-alternating-with-paclitaxel-etoposide-tp-te-therapy.pdf
00212b	In combination with paclitaxel, topotecan (given weekly), or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 10mg/kg therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/212.pdf
00766a	For the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 15mg/kg, carboplatin (auc 6) and paclitaxel 175mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/766-bevacizumab-15mg-kg-carboplatin-auc-6-and-paclitaxel-175mg-m2-therapy.pdf
00215a	In combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 15mg/kg therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/bevacizumab-15mg-kg-21-days.pdf
00215c	In combination with, topotecan given on days 1-5 every 3 weeks*, for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 15mg/kg therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/bevacizumab-15mg-kg-21-days.pdf
00772a	For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 10mg/kg and pegylated liposomal doxorubicin (caelyx®) 40mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/bevacizumab-10mg-kg-and-pegylated-liposomal-doxorubicin-caelyx-40mg-m2-therapy.pdf
00620a	Bevacizumab in combination with CARBOplatin and PACLItaxel is indicated as first line post-surgical treatment in FIGO stage III after surgery with residual disease ≥1cm or FIGO stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 7.5mg/kg, carboplatin (auc5) and paclitaxel 175mg/m2 therapyi	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/bev-7-5mg-kg-carbo-auc5-and-paclitaxel-175mg-m2-therapy.pdf
00769	For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 10mg/kg and paclitaxel 80mg/m2 (day 1, 8, 15 and 22)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/769-bevacizumab-10mg-kg-and-paclitaxel-80mg-m2-day-1-8-15-and-22-therapy.pdf
00771	For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 10mg/kg and topotecan 4mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/771-bevacizumab-10mg-kg-and-topotecan-4mg-m2-therapy.pdf
00716a	Bevacizumab in combination with CARBOplatin and PACLitaxel for the treatment of persistent recurrent or metastatic cervical cancer, not amenable to curative surgery or radiation therapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	bevacizumab 15mg paclitaxel and carboplatin auc 5	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/716-bevacizumab-15mg-paclitaxel-and-carboplatin-auc-5.pdf
00251a	ovarian carcinoma of epithelial origin.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00251b	primary peritoneal carcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00251c	fallopian tube cancer.where combination therapy is not suitable.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00251d	ovarian carcinoma of epithelial origin.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00251e	primary peritoneal carcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00251f	fallopian tube cancer.where surgery is not feasible and where combination therapy is not suitable.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00251g	invasive ovarian carcinoma of epithelial origin.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00251h	primary peritoneal carcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00251i	fallopian tube cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf
00261a	ovarian carcinoma of epithelial origin.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00261b	primary peritoneal carcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00261c	fallopian tube cancer.where combination therapy is not suitable.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00261d	ovarian carcinoma of epithelial origin.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00261e	primary peritoneal carcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00261f	fallopian tube cancer.where surgery is not feasible and where combination therapy is not suitable.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00261g	invasive ovarian carcinoma of epithelial origin.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00261h	primary peritoneal carcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00261i	fallopian tube cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 4 - 6) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf
00303a	Adjuvant treatment of high risk, stage I, epithelial ovarian cancer*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc5 - 7.5) and paclitaxel 175mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/303-carboplatin-auc5-7-5-and-paclitaxel-175mg-m2-therapy.pdf
00303b	Treatment of advanced ovarian cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc5 - 7.5) and paclitaxel 175mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/303-carboplatin-auc5-7-5-and-paclitaxel-175mg-m2-therapy.pdf
00303c	Treatment of primary peritoneal cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc5 - 7.5) and paclitaxel 175mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/303-carboplatin-auc5-7-5-and-paclitaxel-175mg-m2-therapy.pdf
00303d	Treatment of fallopian tube cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc5 - 7.5) and paclitaxel 175mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/303-carboplatin-auc5-7-5-and-paclitaxel-175mg-m2-therapy.pdf
00303e	Treatment of recurrent or advanced endometrial cancer (stage III or IV) *.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc5 - 7.5) and paclitaxel 175mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/303-carboplatin-auc5-7-5-and-paclitaxel-175mg-m2-therapy.pdf
00303f	Treatment of advanced/recurrent non small cell (NSC)cancer of the cervix *.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc5 - 7.5) and paclitaxel 175mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/303-carboplatin-auc5-7-5-and-paclitaxel-175mg-m2-therapy.pdf
00303g	Treatment of carcinoma of unknown primary site*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc5 - 7.5) and paclitaxel 175mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/303-carboplatin-auc5-7-5-and-paclitaxel-175mg-m2-therapy.pdf
00308a	Adjuvant treatment of high risk, stage I, epithelial ovarian cancer*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 6) and weekly paclitaxel 80mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/308-carboplatin-auc-5-6-and-weekly-paclitaxel-80mg-m2-therapy.pdf
00308b	Treatment of advanced ovarian cancer*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 6) and weekly paclitaxel 80mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/308-carboplatin-auc-5-6-and-weekly-paclitaxel-80mg-m2-therapy.pdf
00308c	Treatment of primary peritoneal cancer*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 6) and weekly paclitaxel 80mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/308-carboplatin-auc-5-6-and-weekly-paclitaxel-80mg-m2-therapy.pdf
00308d	Treatment of fallopian tube cancer*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin (auc 6) and weekly paclitaxel 80mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/308-carboplatin-auc-5-6-and-weekly-paclitaxel-80mg-m2-therapy.pdf
00624a	Treatment of patients with platinum sensitive relapsed/ recurrent ovarian cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin auc 5 and pegylated liposomal doxorubicin 30mg/m2 therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/624.pdf
00624b	Treatment of patients with platinum sensitive relapsed/ recurrent primary peritoneal cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin auc 5 and pegylated liposomal doxorubicin 30mg/m2 therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/624.pdf
00624c	Treatment of patients with platinum sensitive relapsed/ recurrent fallopian tube cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	carboplatin auc 5 and pegylated liposomal doxorubicin 30mg/m2 therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/624.pdf
00676a	Adjuvant treatment for high risk, stage I (grade 3 with deep myometrial invasion and/or lymph-vascular invasion) stage II or III endometrial carcinoma or stage I–III endometrial carcinoma with serous or clear cell histology following surgery.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	cisplatin (50mg/m2 ) chemoradiation followed by carboplatin (auc 5) and paclitaxel (175mg/m2 ) - endometrial cancer	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/676.pdf
00203e	Treatment of Relapsed/Progressing primary peritonealcarcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	docetaxel monotherapy 75mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/203.pdf
00203f	Treatment of Relapsed/Progressing Epthelial Ovariancarcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	docetaxel monotherapy 75mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/203.pdf
00203g	Treatment of Relapsed/Progressing Fallopian TubeCarcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	docetaxel monotherapy 75mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/203.pdf
00306a	Treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	gemcitabine 1000mg/m2 and carboplatin (auc 4) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/306.pdf
00306b	Treatment of patients with fallopian tube cancer with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	gemcitabine 1000mg/m2 and carboplatin (auc 4) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/306.pdf
00306c	Treatment of patients with primary peritoneal cancer with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	gemcitabine 1000mg/m2 and carboplatin (auc 4) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/306.pdf
00499a	Treatment of adult patients with first recurrence of platinum-sensitive.epithelial ovarian,.fallopian tube or.primary peritoneal cancer.who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	gemcitabine(1000mg/m2),carboplatin (auc 4) and bevacizumab 15mg/kg therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/499.pdf
00571a	"As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian cancer who are in response (complete or partial response) to platinum-based chemotherapy.
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy."	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	niraparib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/571-niraparib-monotherapy.pdf
00571b	"As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed fallopian tube  cancer who are in response (complete or partial response) to platinum-based chemotherapy.
As monotherapy for the maintenance treatment of adult patients with platinum sensitive fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy."	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	niraparib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/571-niraparib-monotherapy.pdf
00571c	"As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed primary peritoneal  cancer who are in response (complete or partial response) to platinum-based chemotherapy.
As monotherapy for the maintenance treatment of adult patients with platinum sensitive primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy."	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	niraparib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/571-niraparib-monotherapy.pdf
00588a	"Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) high-grade epithelial ovarian cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy.
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) high grade epithelial ovarian cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy."	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	olaparib (tablets)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf
00588b	Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) fallopian tube cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	olaparib (tablets)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf
00588c	Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) primary peritoneal carcinoma who are in response (complete or partial) following completion of first‐line platinum based chemotherapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	olaparib (tablets)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf
00588d	Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) -high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	olaparib (tablets)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf
00588e	Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	olaparib (tablets)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf
00588f	"Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic)  primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy."	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	olaparib (tablets)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf
00205b	Treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	pegylated liposomal doxorubicin 50mg/m2 (caelyx®) 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/205-pegylated-liposomal-doxorubicin-50mg-m2-caelyx-%C2%AE-28-days-regimen.pdf
00226b	Second-line chemotherapy for metastatic ovarian cancer after failure of standard, platinum-containing therapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	paclitaxel monotherapy 80mg/m2 day 1, 8, 15 and 22 - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/226-paclitaxel-monotherapy-80mg-m2-7day-cycle.pdf
00621c	Second-line chemotherapy for metastatic ovarian cancer after failure of standard, platinum-containing therapyi.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	paclitaxel 80mg/m2 day 1, 8 and 15 monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf
00311a	Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	topotecan monotherapy - 5 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/311-topotecan-monotherapy-5-day.pdf
00311c	Treatment of patients with metastatic carcinoma of the fallopian tubes after failure of first-line or subsequent therapy*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	topotecan monotherapy - 5 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/311-topotecan-monotherapy-5-day.pdf
00311d	Treatment of patients with metastatic peritoneal  carcinoma after failure of first-line or subsequent therapy*.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	topotecan monotherapy - 5 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/311-topotecan-monotherapy-5-day.pdf
00312a	Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	topotecan monotherapy-weekly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/312-topotecan-monotherapy-weekly-.pdf
00312b	Treatment of patients with metastatic carcinoma of the fallopian tubes after failure of first-line or subsequent therapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	topotecan monotherapy-weekly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/312-topotecan-monotherapy-weekly-.pdf
00312c	Treatment of patients with metastatic peritoneal  carcinoma after failure of first-line or subsequent therapy.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	topotecan monotherapy-weekly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/312-topotecan-monotherapy-weekly-.pdf
00375a	Treatment of patients with relapsed platinum-sensitive ovarian cancer.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	trabectedin and pegylated liposomal doxorubicin (pld)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/375.pdf
00232c	Platinum refractory advanced ovarian carcinoma.	gynaecology:Ovarian Chemotherapy Regimens, oral-anti-cancer-medicines, gynaecology, sarcoma	intravenous vinorelbine therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/232-intravenous-vinorelbine-therapy-21-days.pdf
00332a	Chemoradiation commencing 3 to 8 weeks after the completion of induction chemotherapy with TPF in patients with Stage III or IV locally advanced squamous cell carcinoma (SCC) of the head and neck.	oral-anti-cancer-medicines, headandneck	carboplatin auc (1.5) chemoradiation therapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/332-carboplatin-auc-1-5-chemoradiation-therapy-7-days.pdf
00419a	Chemoradiation treatment of stage III and IV locally advanced nasopharyngeal carcinoma in patients where CISplatin is contraindicated or not tolerated.	oral-anti-cancer-medicines, headandneck	carboplatin (auc2) weekly with radiotherapy (rt)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/419.pdf
00591a	Locally Advanced Squamous Cell Carcinoma of the Head and Neck.	oral-anti-cancer-medicines, headandneck	carboplatin auc 4 and 5-fluorouracil 600mg/m2 with radiotherapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/591.pdf
00552a	Adjuvant chemotherapy following chemoradiation treatment in patients with locally advanced stage III or IV nasopharyngeal carcinoma where CISplatin is contraindicated or not tolerated.	oral-anti-cancer-medicines, headandneck	carboplatin (auc 5) and 5-fluorouracil 1000mg/m2/day therapy - 28 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/552.pdf
00589a	Locally Advanced Squamous Cell Carcinoma of the Head and Neck.	oral-anti-cancer-medicines, headandneck	carboplatin 70mg/m2 and 5-fluorouracil 600mg/m2 with radiotherapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/589.pdf
00207b	Treatment of patients with squamous cell cancer of the head and neck: In combination with radiation therapy for locally advanced disease.	oral-anti-cancer-medicines, headandneck	cetuximab therapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/207.pdf
00418a	Locally advanced or metastatic squamous cell head and neck cancer where CISplatin is contraindicated or not tolerated.	oral-anti-cancer-medicines, headandneck	cetuximab (weekly), carboplatin auc 5 and 5-fu 1000mg/m2/day therapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/418.pdf
00417a	Locally advanced or metastatic squamous cell carcinoma of the head and neck.	oral-anti-cancer-medicines, headandneck	cetuximab (weekly), cisplatin 100mg/m2 and 5-fluorouracil 1000mg/m2/day therapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/417.pdf
00385c	Chemoradiation treatment for locally advanced nasopharnygeal carcinoma.	oral-anti-cancer-medicines, headandneck	cisplatin 40mg/m2 weekly with radiotherapy (rt)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/385-cisplatin-40mg-m2-weekly-with-radiotherapy-rt-.pdf
00385d	Chemoradiation treatment for locally advanced unresectable head and neck squamous carcinoma (SCC) in patients who cannot tolerate three weekly CISplatin regimens.	oral-anti-cancer-medicines, headandneck	cisplatin 40mg/m2 weekly with radiotherapy (rt)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/385-cisplatin-40mg-m2-weekly-with-radiotherapy-rt-.pdf
00387a	Chemoradiation treatment for locally advanced (stage III to IV) squamous cell carcinoma (SCC) of the head and neck.	oral-anti-cancer-medicines, headandneck	cisplatin 100mg/m2 with radiotherapy (rt)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/387-cisplatin-100-and-rt.pdf
00314a	Locally advanced or metastatic head and neck cancer.	oral-anti-cancer-medicines, headandneck	cisplatin and 5-fluorouracil therapy - 28 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/314-cisplatin-and-5-fluorouracil-therapy-28-day-cycle.pdf
00615a	Treatment of advanced salivary gland cancer.	oral-anti-cancer-medicines, headandneck	cyclophosphamide, doxorubicin and cisplatin therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/615.pdf
00315a	Induction treatment of patients with Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.	oral-anti-cancer-medicines, headandneck	neoadjuvant docetaxel cisplatin 5-fluorouracil and chemoradiation and surgery	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/315-neoadjuvant-docetaxel-cisplatin-5-fluorouracil-and-chemoradiation-and-surgery.pdf
00323a	Induction treatment of patients with locally advanced Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.	oral-anti-cancer-medicines, headandneck	docetaxel,cisplatin ,5-fluorouracil and chemoradiation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/323-docetaxel-cisplatin-5-fluorouracil-and-chemoradiation-therapy.pdf
00324a	Induction treatment followed by radiotherapy of patients with Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.	oral-anti-cancer-medicines, headandneck	docetaxel cisplatin 5-fluorouracil and radiotherapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/324-docetaxel-cisplatin-5-fluorouracil-and-radiotherapy.pdf
00514a	Loco-regionally recurrent/metastatic nasopharyngeal cancer not amenable for local curative therapy.	oral-anti-cancer-medicines, headandneck	gemcitabine (1250mg/m2) monotherapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/514-gemcitabine-1250mg-m2-monotherapy-21-day.pdf
00517a	Treatment of locally advanced nasopharyngeal cancer.	oral-anti-cancer-medicines, headandneck	gemcitabine (1250mg/m2) and cisplatin (80mg/m2) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/517-gemcitabine-1250mg-m2-and-cisplatin-80mg-m2-therapy-21-day.pdf
00295a	Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.	oral-anti-cancer-medicines, headandneck	lenvatinib - dtc therapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/295.pdf
00483d	As monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.	oral-anti-cancer-medicines, headandneck	nivolumab 240mg monotherapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/483-nivolumab-240mg-monotherapy.pdf
00484e	As monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.	oral-anti-cancer-medicines, headandneck	nivolumab 480mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf
00455h	As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.	oral-anti-cancer-medicines, headandneck	pembrolizumab 200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf
00558h	As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.	oral-anti-cancer-medicines, headandneck	pembrolizumab 400mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/558-pembrolizumab-400-mg-monotherapy.pdf
00705a	Pembrolizumab is indicated, in combination with CARBOplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.	oral-anti-cancer-medicines, headandneck	pembrolizumab, carboplatin (auc5) and 5-fluorouracil	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/705-pembrolizumab-carboplatin-and-5-fu-therapy.pdf
00706a	Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.	oral-anti-cancer-medicines, headandneck	pembrolizumab, cisplatin and 5-fluorouracil	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/706-pembrolizumab-cisplatin-and-5-fu-therapy.pdf
00294c	"Treatment of patients with progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine."	oral-anti-cancer-medicines, headandneck	sorafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/294-sorafenib-therapy.pdf
00242a	"Treatment of aggressive and symptomatic MTC in patients with unresectable locally advanced or metastatic disease.
Treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease."	oral-anti-cancer-medicines, headandneck	vandetanib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdf
00656a	As monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	acalabrutinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/656-acalabrutinib-monotherapy.pdf
00656b	As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	acalabrutinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/656-acalabrutinib-monotherapy.pdf
00287a	Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	azacitidine 75mg/m2 5 - 2 - 2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/287-azacitidine-75mg-m2-5-2-2-therapy.pdf
00287b	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Intermediate-2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	azacitidine 75mg/m2 5 - 2 - 2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/287-azacitidine-75mg-m2-5-2-2-therapy.pdf
00287c	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	azacitidine 75mg/m2 5 - 2 - 2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/287-azacitidine-75mg-m2-5-2-2-therapy.pdf
00287d	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Acute myeloid leukaemia (AML) with20-30% blasts and multi-lineage dysplasia, according to WHO classification.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	azacitidine 75mg/m2 5 - 2 - 2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/287-azacitidine-75mg-m2-5-2-2-therapy.pdf
00288a	Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	azacitidine 100mg/m2 5-day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/288-azacitidine-100mg-m2-5-day-therapy.pdf
00288b	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Intermediate-2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	azacitidine 100mg/m2 5-day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/288-azacitidine-100mg-m2-5-day-therapy.pdf
00288c	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	azacitidine 100mg/m2 5-day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/288-azacitidine-100mg-m2-5-day-therapy.pdf
00288d	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to WHO classification.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	azacitidine 100mg/m2 5-day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/288-azacitidine-100mg-m2-5-day-therapy.pdf
00527a	Treatment of patients with relapsed or refractory Chronic Lymphocytic Leukaemia (CLL).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	bendamustine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/527-bendamustine-monotherapy.pdf
00538a	Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	blinatumomab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/538-blinatumomab-therapy.pdf
00590a	As monotherapy for the treatment of adults with Philadelphiachromosome negative CD19 positive B-precursor acute lymphoblasticleukaemia (ALL) in first or second complete remission with minimalresidual disease (MRD) greater than or equal to 0.1%.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	blinatumomab therapy (all with mrd ≥ 0.1%)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/590-blinatumomab-mrd.pdf
00224a	"Treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+CML previously treated with one or more TKI(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Treatment of adult patients with chronic phase (CP), accelerate phase (AP), and blast phase (BP) Philadelphia choromosome positive chronic myelogenous leukaemia (Ph+CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotonib and dasatinib are not considered appropriate treatment options."	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	bosutinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/224-bosutinib-monotherapy-regimen.pdf
00411b	Treatment of patients with Chronic Lymphocytic Leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	chlorambucil 10mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/411-chlorambucil-10mg-m2-therapy.pdf
00402a	First line treatment for adult patients with Hairy Cell Leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	cladribine 0.14mg/day day 1 to 5	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/402-cladribine-0-14mg-day-day-1-to-5-therapy.pdf
00469a	First line treatment for adult patients with Hairy Cell Leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	cladribine 0.14mg/kg weekly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/469-cladribine-0-14mg-kg-weekly-therapy.pdf
00534a	Treatment for adult patients with relapsed or partially responsive  Hairy Cell Leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	cladribine weekly and rituximab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/534-cladribine-weekly-and-rituximab-therapy.pdf
00531a	Treatment for adult patients with relapsed or partially responsive  Hairy Cell Leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	cladribine 5 day and rituximab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/531-cladribine-5-day-and-rituximab-therapy.pdf
00365a	Consolidation chemotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	high dose cytarabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/365.pdf
00364a	Consolidation chemotherapy for the treatment of patients Acute Myeloid Leukaemia (AML).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	intermediate dose cytarabine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/364.pdf
00359a	Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	da(60/100) 3+10: course 1 induction therapy (aml - 17)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/359.pdf
00360a	Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	da (50/100) (3+8) course 2 induction therapy (aml - 17)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/360.pdf
00231a	Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary AML, according to the WHO classification, who are not candidates for standard induction chemotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	decitabine monotherapy - aml (28 day cycle)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/231.pdf
00788a	For the treatment of disease-related splenomegaly or symptoms in adult patients with:primary myelofibrosis (PMF),post polycythaemia vera myelofibrosis (PVMF) or post essential thrombocythaemia myelofibrosis (ET MF) who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	fedratinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/788-fedratinib-therapy.pdf
00363a	Treatment of Acute Myeloid Leukaemia (AML) in patients unsuitable for treatment with idarubicin or as consolidation post FLAG-Ida.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	flag	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/363 flag therapy regimen .pdf
00363b	Treatment of patients with high blast count (&gt;10%) Myelodysplastic Syndrome in patients unsuitable for treatment with idarubicin.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	flag	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/363 flag therapy regimen .pdf
00363c	Salvage regimen for patients with relapsed/refractory acute leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	flag	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/363 flag therapy regimen .pdf
00362a	Induction of chemotherapy regimen for the treatment of patients with de novo, secondary Acute Myeloid Leukaemia (AML), or biphenotypic leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	flag: ida 8mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/362-flag-ida-8mg-m2-therapy.pdf
00362b	Treatment of patients with blast count (&gt;10%) Myelodysplastic Syndrome.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	flag: ida 8mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/362-flag-ida-8mg-m2-therapy.pdf
00362c	Salvage regimen for patients with relapsed/refractory acute leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	flag: ida 8mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/362-flag-ida-8mg-m2-therapy.pdf
00241a	Treatment of B-cell chronic lymphocytic leukaemia (CLL).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	fludarabine, cyclophosamide and rituximab ( fc (iv) and r)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/241.pdf
00410a	Treatment of B-cell chronic lymphocytic leukaemia (CLL).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	fludarabine, cyclophosphamide and rituximab (fc oral+r)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/410-fcoral-and-r-fludarabine-cyclophosamide-and-rituximab-fc-oral-and-r-therapy.pdf
00612a	Gemtuzumab ozogamicin is indicated for combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukaemia (AML), except acute promyeloytic leukaemia.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	gemtuzumab ozogamicin, daunorubicin and cytarabine therapy (aml induction)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/612-gemtuzumab-ozogamicin-therpay.pdf
00296a	As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	ibrutinib therapy (cll/ waldenstrom's macroglobulinaemia)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf
00296b	As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	ibrutinib therapy (cll/ waldenstrom's macroglobulinaemia)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf
00296c	As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	ibrutinib therapy (cll/ waldenstrom's macroglobulinaemia)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf
00389a	In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	idelalisib and rituximab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf
00389b	In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	idelalisib and rituximab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf
00537a	Monotherapy for the treatment of adults with relapsed or refractory CD22- positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	inotuzumab ozogamicin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/537-inotuzumab-ozogamicin-monotherapy.pdf
00661a	Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	midostaurin maintenance	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/661.pdf
00682a	"Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.
Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine inductionchemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive."	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	midostaurin (daunorubicin and cytarabine) induction	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/682.pdf
00683a	Midostaurin is indicated in combination with intermediate dose cytarabine consolidation.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	midostaurin and intermediate dose cytarabine consolidation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/683-midostaurin-intermediate-dose-cytarabine-consolidation-therapy.pdf
00286a	Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	obinutuzumab and chlorambucil	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/286 obinutuzumab-and-chlorambucil-therapy.pdf
00302a	Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	ponatinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/302.pdf
00302b	Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	ponatinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/302.pdf
00229a	"Primary myelofibrosis (chronic idiopathic myelofibrosis).
Treatment of disease related splenmegaly or symptoms in adult patients with primary myelofibrosis (chronic idiopathic myelofibrosis)."	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	ruxolitinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/229-ruxolitinib-monotherapy-regimen.pdf
00229b	Post polycythaemia vera myelofibrosis.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	ruxolitinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/229-ruxolitinib-monotherapy-regimen.pdf
00229c	Post essential thrombocythaemia myelofibrosis.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	ruxolitinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/229-ruxolitinib-monotherapy-regimen.pdf
00356a	Treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	tretinoin (atra) with arsenic trioxide (ato) induction	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf
00357a	"Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356).
Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356."	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	tretinoin (atra) with arsenic trioxide (ato) consolidation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/357-tretinoin-atra-with-arsenic-trioxide-ato-consolidation-therapy.pdf
00366a	"Treatment of patients with newly diagnosed high risk Acute Promyelocytic Leukaemia (APL).
Treatment of patients with newly diagnosed Acute Promyelocytic Leukaemia (APL)."	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	tretinoin (atra) / idarubicin (pethema aida) induction therapy: high risk	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/366-tretinoin-atra-idarubicin-pethema-aida-induction-therapy-high-risk.pdf
00400a	Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	venetoclax	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf
00400b	Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	venetoclax	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf
00715a	In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	venetoclax and obinutuzumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/715.pdf
00575a	Venetoclax in combination with riTUXimab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	venetoclax and rituximab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/575-venetoclax-and-rituximab-therapy.pdf
00613a	For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	vyxeos liposomal® daunorubicin and cytarabine induction	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/613-vxyeos-%C2%AE-liposomal-daunorubicin-and-cytarabine-induction-therapy.pdf
00618a	For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).	oral-anti-cancer-medicines, lymphoma-myeloma, leukemia-bmt	vyxeos liposomal® daunorubicin and cytarabine consolidation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/618-vxyeos%C2%AE-liposomal-daunorubicin-and-cytarabine-consolidation-therapy.pdf
00221a	"Treatment of EGFR TKI- naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s).
Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)."	oral-anti-cancer-medicines, lung	afatinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/221.pdf
00401a	Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	oral-anti-cancer-medicines, lung	alectinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401 .pdf
00401b	"As monotherapy is indicated for the first-line treatment of adultpatients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)."	oral-anti-cancer-medicines, lung	alectinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401 .pdf
00544a	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.	oral-anti-cancer-medicines, lung	atezolizumab 1200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf
00544d	first-line treatment of adult patients withmetastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltratingimmune cells (IC) and who do not have EGFR mutant or ALK-positiveNSCLC.	oral-anti-cancer-medicines, lung	atezolizumab 1200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf
00593a	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.	oral-anti-cancer-medicines, lung	atezolizumab 1680mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf
00593d	First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.	oral-anti-cancer-medicines, lung	atezolizumab 1680mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf
00592d	As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.	oral-anti-cancer-medicines, lung	atezolizumab 840mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf
00689a	First-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	oral-anti-cancer-medicines, lung	atezolizumab 1200mg, carboplatin auc 5 and etoposide 100mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/689.pdf
00214b	In addition to platinum-based chemotherapy is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.	oral-anti-cancer-medicines, lung	bevacizumab 7.5 mg/kg - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/bevacizumab7-5v7214.pdf
00215f	In addition to platinum-based chemotherapy is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.	oral-anti-cancer-medicines, lung	bevacizumab 15mg/kg therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/215.pdf
00215g	In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations.	oral-anti-cancer-medicines, lung	bevacizumab 15mg/kg therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/215.pdf
00562a	For the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	oral-anti-cancer-medicines, lung	brigatinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf
00562b	Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.	oral-anti-cancer-medicines, lung	brigatinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf
00271a	Small cell lung cancer (SCLC) extensive disease.	oral-anti-cancer-medicines, lung	carboplatin (auc5) and etoposide 100mg/m2 therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/271.pdf
00319a	Small cell lung cancer (SCLC) extensive disease.	oral-anti-cancer-medicines, lung	carboplatin and oral etoposide therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/319-carboplatin-and-oral-etoposide-therapy-21-days.pdf
00304a	Adjuvant Treatment of Stage I,II and IIIA Non Small Cell Lung Cancer( NSCLC)*.	oral-anti-cancer-medicines, lung	carboplatin (auc6) and paclitaxel 200mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/304-carboplatin-auc6-and-paclitaxel-200mg-m2-therapy-.pdf
00304b	Treatment of locally advanced, recurrent or metastatic NSCLC*.	oral-anti-cancer-medicines, lung	carboplatin (auc6) and paclitaxel 200mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/304-carboplatin-auc6-and-paclitaxel-200mg-m2-therapy-.pdf
00309a	Stage III Non small cell lung cancer (NSCLC)*.	oral-anti-cancer-medicines, lung	weekly carboplatin (auc2) and paclitaxel 50mg/m2 therapy with radiotherapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/309-weekly-carboplatin-auc2-and-paclitaxel-50mg-m2-therapy-with-radiotherapy.pdf
00614a	Treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) in patients not suitable for treatment with CISplatin.	oral-anti-cancer-medicines, lung	carboplatin and vinorelbine therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/614.pdf
00340a	Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	oral-anti-cancer-medicines, lung	ceritinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/340-ceritinib-monotherapy.pdf
00280a	Small cell lung cancer (SCLC) extensive disease.	oral-anti-cancer-medicines, lung	cisplatin and etoposide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/280%20ver%204.pdf
00279a	Small cell lung cancer (SCLC) limited disease.	oral-anti-cancer-medicines, lung	cisplatin and etoposide and thoracic radiotherapy (trt)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/279-nccp-cisplatin-and-etoposide-ver2final.pdf
00456a	Stage III Non Small cell lung cancer (NSCLC).	oral-anti-cancer-medicines, lung	cisplatin (50mg/m2) and etoposide (50mg/m2) and thoracic radiotherapy (trt) - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/456-cisplatin-50mg-m2-and-etoposide-50mg-m2-and-thoracic-radiotherapy-trt-28-day.pdf
00243a	"Treatment of adults with previously treated ALK-positive advanced NSCLC.
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)."	oral-anti-cancer-medicines, lung	crizotinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf
00243b	"The treatment of adults with ROS1-positive advanced non-small celllung cancer (NSCLC).
The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)."	oral-anti-cancer-medicines, lung	crizotinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf
00243c	"First-line treatment of adults with anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer (NSCLC).
First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)."	oral-anti-cancer-medicines, lung	crizotinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf
00565a	Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.	oral-anti-cancer-medicines, lung	dacomitinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/565-dacomitinib-monotherapy.pdf
00203a	Treatment of locally advanced or metastatic NSLC after failure of prior chemotherapy.	oral-anti-cancer-medicines, lung	docetaxel monotherapy 75mg/m2 - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf
00576a	As monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).	oral-anti-cancer-medicines, lung	durvalumab 10mg/kg monotherapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/576.pdf
00655a	As monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).	oral-anti-cancer-medicines, lung	durvalumab 1500mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/655-durvalumab-1500mg-monotherapy-28-day.pdf
00702a	As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.	oral-anti-cancer-medicines, lung	entrectinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf
00219a	First-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations.	oral-anti-cancer-medicines, lung	erlotinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf
00219b	Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy.	oral-anti-cancer-medicines, lung	erlotinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf
00219c	Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.	oral-anti-cancer-medicines, lung	erlotinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf
00388a	Small cell lung cancer (SCLC) extensive disease in patients unsuitable for intravenous or combination chemotherapy.	oral-anti-cancer-medicines, lung	oral etoposide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/388.pdf
00220a	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.	oral-anti-cancer-medicines, lung	gefitinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/220-gefitinib-monotherapy.pdf
00284b	Treatment of elderly patients or patients with ECOG =2 with locally advanced or metastatic non-small cell lung cancer (NSCLC).	oral-anti-cancer-medicines, lung	gemcitabine 1000mg/m2 monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/284-gemcitabine-1000mg-m2-monotherapy-28-day.pdf
00310b	Treatment of patients with locally advanced, recurrent or metastatic non small cell lung cancer (NSCLC)*.	oral-anti-cancer-medicines, lung	gemcitabine (1000mg/m2) and carboplatin (auc5) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf
00281a	Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).	oral-anti-cancer-medicines, lung	gemcitabine (1250mg/m2) and cisplatin 75mg/m2 therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/281-gemcitabine-1250mg-m2-and-cisplatin-75mg-m2-therapy-21days.pdf
00570a	"As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on.(i) alectinib or ceritinib as the first ALK-targeted treatment.or.(ii) crizotinib and at least one other ALK-targeted treatment.
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on.(i) alectinib or ceritinib as the first ALK-targeted treatment or.(ii) crizotinib and at least one other ALK-targeted treatment."	oral-anti-cancer-medicines, lung	lorlatinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf
00570b	As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor.	oral-anti-cancer-medicines, lung	lorlatinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf
00372a	"In combination with docetaxel for the treatment of adult patients with locally advanced, metastatic of stage IIIB or IV, or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.
Treatment of adult patients with locally advanced, metastatic of stage IIIB or IV, or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy."	oral-anti-cancer-medicines, lung	nintedanib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/372.pdf
00483e	As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	oral-anti-cancer-medicines, lung	nivolumab monotherapy 240mg - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/483-nivolumab-240mg-monotherapy.pdf
00484f	As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer (NSCLC) after prior chemotherapy in adults.	oral-anti-cancer-medicines, lung	nivolumab monotherapy 480mg - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf
00712a	First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	oral-anti-cancer-medicines, lung	nivolumab, ipilimumab, carboplatin and paclitaxel	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/712.pdf
00713a	First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	oral-anti-cancer-medicines, lung	nivolumab, ipilimumab, pemetrexed and carboplatin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/713.pdf
00714a	First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	oral-anti-cancer-medicines, lung	nivolumab, ipilimumab, pemetrexed and cisplatin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/714.pdf
00353a	Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).	oral-anti-cancer-medicines, lung	osimertinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf
00353b	"First-line treatment of adult patients with locally advanced or metastaticnon-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations."	oral-anti-cancer-medicines, lung	osimertinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf
00226d	Relapsed or refractory small cell lung cancer.	oral-anti-cancer-medicines, lung	paclitaxel monotherapy 80mg/m2 day 1, 8, 15 and 22 - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/226-paclitaxel-monotherapy-80mg-m2-7day-cycle.pdf
00621d	Relapsed or refractory small cell lung cancer.	oral-anti-cancer-medicines, lung	paclitaxel 80mg/m2 day 1, 8 and 15 monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf
00455a	First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.	oral-anti-cancer-medicines, lung	pembrolizumab 200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf
00558a	First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.	oral-anti-cancer-medicines, lung	pembrolizumab 400 mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/pembrolizumab-400mg-monotherapy-558.pdf
00579a	Pembrolizumab In Combination with CARBOplatin and PACLitaxel for the first-line treatment of Patients with metastatic Squamous Non-Small Cell Lung Cancer (NSCLC).	oral-anti-cancer-medicines, lung	pembrolizumab, paclitaxel and carboplatin (auc 6)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/579.pdf
00568a	Pembrolizumab is indicated in combination with PEMEtrexed and CARBOplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations.	oral-anti-cancer-medicines, lung	pembrolizumab, pemetrexed and carboplatin (auc 5)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/568.pdf
00569a	Pembrolizumab is indicated in combination with PEMEtrexed and CISplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations.	oral-anti-cancer-medicines, lung	pembrolizumab, pemetrexed and cisplatin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/569.pdf
00222a	Maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients who disease has not progressed immediately following platinum-based chemotherapy.	oral-anti-cancer-medicines, lung	pemetrexed	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/222-pemetrexed-monotherapy-regimen.pdf
00222b	Second line treatment of patients with locally advanced or metastatic NSLC other than predominantly squamous cell histology.	oral-anti-cancer-medicines, lung	pemetrexed	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/222-pemetrexed-monotherapy-regimen.pdf
00318a	Treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.	oral-anti-cancer-medicines, lung	pemetrexed and carboplatin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/318-pemetrexed-and-carboplatin-therapy.pdf
00318b	First line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.	oral-anti-cancer-medicines, lung	pemetrexed and carboplatin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/318-pemetrexed-and-carboplatin-therapy.pdf
00317a	Treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.	oral-anti-cancer-medicines, lung	pemetrexed and cisplatin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/317-pemetrexed-and-cisplatin-therapy.pdf
00317b	First line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).	oral-anti-cancer-medicines, lung	pemetrexed and cisplatin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/317-pemetrexed-and-cisplatin-therapy.pdf
00311b	Treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.	oral-anti-cancer-medicines, lung	topotecan monotherapy - 5 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/311-topotecan-monotherapy-5-day.pdf
00587a	"Treatment of adult patients with relapsed small cell lung cancer(SCLC) for whom re-treatment with the first –line regimen is notconsidered appropriate.
Treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first –line regimen is not considered appropriate."	oral-anti-cancer-medicines, lung	topotecan oral	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/587-topotecan-oral-monotherapy.pdf
00259b	Non small cell lung cancer (NSLC).	oral-anti-cancer-medicines, lung	oral vinorelbine monotherapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/259.pdf
00232b	Non small cell lung cancer (NSLC).	oral-anti-cancer-medicines, lung	intravenous vinorelbine therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/232-intravenous-vinorelbine-therapy-21-days.pdf
00343a	Adjuvant treatment of patients with completely resected stage IB, ll or lllA non small cell lung cancer (NSLC).	oral-anti-cancer-medicines, lung	vinorelbine and cisplatin therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/343-vinorelbine-and-cisplatin-therapy-28-days.pdf
00343b	Treatment of locally advanced recurrent or metastatic NSCLC.	oral-anti-cancer-medicines, lung	vinorelbine and cisplatin therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/343-vinorelbine-and-cisplatin-therapy-28-days.pdf
00339a	Adjuvant treatment of patients with completely resected stage IB, ll or lllA non small cell lung cancer (NSLC).	oral-anti-cancer-medicines, lung	vinorelbine 30 (day 1, 8, 15) and cisplatin 80 (day 1) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/339-vinorelbine-30-day-1-8-15-and-cisplatin-80-day-1-therapy-21-day.pdf
00339b	Treatment of locally advanced recurrent or metastatic NSCLC.	oral-anti-cancer-medicines, lung	vinorelbine 30 (day 1, 8, 15) and cisplatin 80 (day 1) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/339-vinorelbine-30-day-1-8-15-and-cisplatin-80-day-1-therapy-21-day.pdf
00290a	Hodgkin’s Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	abvd	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/290-abvd-therapy.pdf
00234a	Following autologous stem cell transplant (ASCT).or.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf
00234b	Following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf
00234c	Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf
00234d	Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf
00234e	Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf
00529a	Treatment of adult patients with relapsed or refractory CD30+ Hodgkinlymphoma (HL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin and bendamustine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/529-brentuximab-vedotin-and-bendamustine-therapy.pdf
00530a	Treatment of adult patients with relapsed/refractory CD30+ Hodgkin’s lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin and eshap therapy(breshap)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdf
00801a	Brentuximab vedotin in combination with cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin and cyclophosphamide, doxorubicin and prednisolone (chp)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/801-brentuximab-vedotin-and-cyclophosphamide-doxorubicin-and-prednisolone-chp-therapy.pdf
00528	Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	brentuximab vedotin and ice	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf
00411a	Treatment of patients with low grade lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	chlorambucil 10mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/411-chlorambucil-10mg-m2-therapy.pdf
00396a	Treatment of T-cell Non-Hodgkins Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	choep therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/396.pdf
00438a	Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	cyclophosphamide 2000mg/m2 for stem cell mobilisation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/438-cyclophosphamide-2000mg-m2-for-stem-cell-mobilisation.pdf
00795a	Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	cyclophosphamide 1500mg/m2 for stem cell mobilisation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/795-cyclophosphamide-for-stem-cell-mobilisation.pdf
00532a	"Treatment of symptomatic treatment naive or relapsed/refractory Waldenstrom’s macroglobulinaemia.
Treatment of Symptomatic treatment naive or relapsed/refractoryWaldenstrom’s macroglobulinaemia."	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	dexamethasone, rituximab and cyclophosphamide (drc)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/532-dexamethasone-rituximab-and-cyclophosphamide-therapy.pdf
00355a	Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins lymphoma (NHL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	dose adjusted r-epoch	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/355-dose-adjusted-r-epoch-therapy.pdf
00354a	Treatment of patients with high risk, advanced stage Hodgkin Lymphoma (IPS ≥ 3).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	escalated dose beacopp 21 day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/354-escalated-dose-beacopp-21-day-therapy.pdf
00354b	Escalation of treatment of patients with Hodgkin Lymphoma after failure to reach complete metabolic response post 2 cycles of ABVD.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	escalated dose beacopp 21 day	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/354-escalated-dose-beacopp-21-day-therapy.pdf
00297a	As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	ibrutinib therapy (mantle cell lymphoma)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/297.pdf
00291a	Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	idelalisib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/291.pdf
00508a	Treatment of primary CNS lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	high dose methotrexate, high dose cytarabine, rituximab and thiotepa (matrix)therapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/508-high-dose-methotrexate-high-dose-cytarabine-rituximab-and-thiotepa-matrix-therapy.pdf
00508b	Treatment of CNS relapse of a high grade systemic lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	high dose methotrexate, high dose cytarabine, rituximab and thiotepa (matrix)therapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/508-high-dose-methotrexate-high-dose-cytarabine-rituximab-and-thiotepa-matrix-therapy.pdf
00483c	As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	nivolumab 240mg monotherapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/483-nivolumab-240mg-monotherapy.pdf
00484d	As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	nivolumab 480mg - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/484-nivolumab-monotherapy-480mg-28-days.pdf
00393a	Mantle Cell Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	nordic therapy protocol	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/393-nordic-therapy-regimen.pdf
00425a	Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment with obinutuzumab and chemotherapy (CHOP, CVP or bendamustine) or have stable disease.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	obinutuzumab maintenance therapy - 56 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/425%20obinutuzumab-maintenance-therapy-following-o-bendamustine-therapy1.pdf
00424a	Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	obinutuzumab and bendamustine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/424-obinutuzumab-and-bendamustine-therapy.pdf
00424b	Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	obinutuzumab and bendamustine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/424-obinutuzumab-and-bendamustine-therapy.pdf
00550a	Obinutuzumab in combination with CVP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	obinutuzumab cyclophosphamide vincristine and prednisolone (o- cvp) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/550-obinutuzumab-cyclophosphamide-vincristine-and-prednisolone-o-cvp-therapy%E2%80%93-21-days.pdf
00549a	Obinutuzumab in combination with CHOP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	obinutuzumab and chop therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/549-obinutuzumab-and-chop-therapy-%E2%80%93-21-day.pdf
00455i	As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	pembrolizumab 200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf
00558i	As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	pembrolizumab 400mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/pembrolizumab-400mg-monotherapy-558.pdf
00255a	Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL).The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	pixantrone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/255-nccp-pixantrone-ver2final-.pdf
00536a	Is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	plerixafor and g-csf	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/536-plerixafor-and-g-csf-therapy.pdf
00685a	Polatuzumab Vedotin in combination with bendamustine and riTUXimab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	polatuzumab vedotin, bendamustine and rituximab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/685-polatuzumab-vedotin-therapy.pdf
00664a	Treatment of newly diagnosed primary CNS lymphoma (PCNSL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab, methotrexate, procarbazine and vincristine (r-mpv) - 14 days induction	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/664-rituximab-methotrexate-procarbazine-and-vincristine-r-mpv-14-days-induction-therapy.pdf
00666a	Consolidation chemotherapy for the treatment of patients with newly diagnosed primary CNS lymphoma (PCNSL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	high dose cytarabine consolidation therapy (post rmpv) - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/666-high-dose-cytarabine-consolidation-therapy-post-rmpv-28-day-therapy.pdf
00540a	Maintenance therapy for the treatment of relapsed/refractory follicular CD20positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who haveresponded to induction therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab 375 mg/m2 maintenance therapy - 84 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdf
00541a	First line treatment of follicular lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab 375 mg/m2 therapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/541-rituximab-375-mg-m2-therapy-7-day.pdf
00541b	As monotherapy for induction treatment for adult patients with stageIII-IV follicular lymphoma who are chemoresistant or are in their secondor subsequent relapse after chemotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab 375 mg/m2 therapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/541-rituximab-375-mg-m2-therapy-7-day.pdf
00541c	As monotherapy for retreatment of patients who have responded toprevious treatment with riTUXimab monotherapy forrelapsed/refractory follicular lymphoma,.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab 375 mg/m2 therapy - 7 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/541-rituximab-375-mg-m2-therapy-7-day.pdf
00542a	In combination with chemotherapy for induction treatment ofpreviously untreated or relapsed/ refractory CD 20 positive patientswith follicular lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab 375 mg/m2 combination therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf
00543a	Maintenance therapy for the treatment of previously untreated follicularCD20 positive, B-cell Non Hodgkin Lymphoma patients responding toinduction therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab 375 mg/m2 maintenance therapy - 56 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/543-rituximab-375-mg-m2-maintenance-therapy-56-day.pdf
00599a	Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab (s/c 1400mg) maintenance therapy - 84 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/599.pdf
00600a	Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab (s/c 1400mg) maintenance therapy - 56 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/600.pdf
00345a	Treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab and bendamustine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/345.pdf
00345b	Treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab and bendamustine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/345.pdf
00510a	"Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.
Treatment of Non Hodgkin CD20 positive Lymphoma for patients not."	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab, cyclophosphamide, etoposide, vincristine prednisolone (r-ceop) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf
00409a	Treatment of Non Hodgkins Lymphoma (NHL)*.*Rituximab to be included in CD20 positive patients.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(*rituximab) cyclophosphamide, doxorubicin, vincristine and prednisolone (*r)-chop therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/409.pdf
00307a	Treatment of Non Hodgkins Lymphoma (NHL).*.*Rituximab to be included in CD20 positive patients.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(*rituximab) cyclophosphamide, doxorubicin, vincristine and prednisolone (*r)-chop) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/307.pdf
00436a	Treatment of Non Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(r**)- minichop therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/436-r-minichop-therapy-%E2%80%93-21-days.pdf
00398a	Treatment of Burkitt Lymphoma in patients less than or equal to 65 years.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	r-codox-m therapy patients less than or equal to 65 years	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/398-r-codox-m-therapy-patients-less-than-or-equal-to-65-years-.pdf
00403a	Treatment of Burkitt Lymphoma in patients aged greater than 65 years.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	r-codox-m therapy patients greater than 65 years	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/403-r-codox-m-therapy-patients-greater-than-65-years-.pdf
00395a	Treatment of relapsed Non Hodgkin Lymphoma**.**Rituximab to be included in CD20 positive patients.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(r**)-dhap	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/395-r-dhap-therapy.pdf
00395b	Treatment of relapsed Hodgkins Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(r**)-dhap	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/395-r-dhap-therapy.pdf
00394a	Treatment of relapsed Non Hodgkin Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(r**)-eshap	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/394-r-eshap-therapy.pdf
00394b	Treatment of relapsed Hodgkins Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(r**)-eshap	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/394-r-eshap-therapy.pdf
00441a	Treatment of relapsed Non Hodgkin Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab** gemcitabine and cisplatin ((r**)-gdp)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/441-rituximab-gemcitabine-dexamethasone-and-cisplatin-r-gdp-therapy.pdf
00441b	Treatment of relapsed Hodgkin’s Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab** gemcitabine and cisplatin ((r**)-gdp)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/441-rituximab-gemcitabine-dexamethasone-and-cisplatin-r-gdp-therapy.pdf
00506a	Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	r-gemcitabine (1000mg/m2) oxaliplatin therapy[i] - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdf
00466a	Treatment of adult patients with mantle cell lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab-hyper cvad therapy (mcl)-part a	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/466-rituximab-hyper-cvad-therapy-mcl-part-a.pdf
00467a	Treatment of adult patients with mantle cell lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	rituximab-methotrexate and cytarabine therapy (mcl)-hyper cvad part b	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/467-rituximab-methotrexate-and-cytarabine-therapy.pdf
00397a	Treatment of relapsed/refractory Non Hodgkin’s Lymphoma**.**Rituximab to be included in CD20 positive patients.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(r**)-ice ((rituximab), ifosfamide, carboplatin and etoposide)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdf
00397b	Treatment of relapsed/refractory Hodgkin’s Lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(r**)-ice ((rituximab), ifosfamide, carboplatin and etoposide)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdf
00399a	Treatment of patients with extensive stage  Burkitt Lymphoma aged less than or equal to 65 years.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	r-ivac therapy patients less than or equal to 65 years	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/399-r-ivac-therapy-patients-less-than-or-equal-to-65-years-.pdf
00404a	Treatment of patients with extensive Burkitt Lymphoma aged greater than  65 years.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	r-ivac	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/404-r-ivac-therapy-patients-greater-than-65-years-.pdf
00293a	First line treatment for patients with stage 3/4 follicular lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(*rituximab) cyclophosphamide and prednisolone (r*)-cvp ) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/293.pdf
00293b	Treatment of patients with relapsed/refractory low grade B cell Non Hodgkin’s lymphoma (NHL)*.*Rituximab to be included in CD20 positive patients.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(*rituximab) cyclophosphamide and prednisolone (r*)-cvp ) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/293.pdf
00737a	Treatment of high-grade non-Hodgkin Lymphoma in patients who are unsuitable for R-CHOP due to impaired cardiac function or other comorbidities*.*riTUXimab to be included in CD20 positive patients.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	(*rituximab)-gemcitabine cyclophosphamide vincristine and prednisolone (*r)-gcvp) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/737-rituximab-gemcitabine-cyclophosphamide-vincristine-and-prednisolone-r-gcvp-therapy21-days.pdf
00277a	Treatment of adult patients with Multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	siltuximab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/277-siltuximab.pdf
00407a	Newly diagnosed stage II- IV or relapsed/refractory extranodal natural killer/T-cell lymphoma.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	smile therapy (nk or t cell lymphoma)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/407-smile-therapy-nk-or-t-cell-lymphoma-.pdf
00708	As monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM), who have received at least one prior therapy oras first line treatment for patients unsuitable for chemo-immunotherapy.	oral-anti-cancer-medicines, lymphoma-myeloma, myeloma	zanubrutinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf
00270a	Treatment of adult patients with progressive multiple myeloma who have received at least one prior therapy.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib and dexamethasone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/270.pdf
00435a	Maintenance treatment for patients with high risk  multiple myeloma.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib maintenance therapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/435-bortezomib-maintenance-therapy-14-day-.pdf
00416a	Treatment of newly diagnosed myeloma in adult patients with high risk features.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib, lenalidomide and dexamethasone (rvd) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/416.pdf
00416b	Treatment of relapsed or refractory myeloma that has received prior therapy in adult patients with high risk features.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib, lenalidomide and dexamethasone (rvd) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/416.pdf
00643a	Treatment of Myeloma.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib, lenalidomide and dexamethasone (rvd) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/643.pdf
00275a	Treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib, melphalan and prednisolone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/275-bortezomib-melphalan-and-prednisolone-therapy.pdf
00780a	Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible C.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib, lenalidomide and dexamethasone (rvd-lite) induction	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/780-bortezomib-lenalidomide-and-dexamethasone.pdf
00781a	Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction therapy.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib and lenalidomide (rvd-lite) consolidation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/781-bortezomib-and-lenalidomide-rvd-lite-consolidation-therapy.pdf
00782a	Indicated as single agent maintenance therapy in patients with newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction and consolidation therapy.	oral-anti-cancer-medicines, transplant, myeloma	lenalidomide maintenance therapy (rvd-lite)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/782-lenalidomide-maintenance-therapy-rvd-lite-.pdf
00274a	Bortezomib, thalidomide and dexamethasone for induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.	oral-anti-cancer-medicines, transplant, myeloma	bortezomib, thalidomide and dexamethasone (vtd) induction	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/274-bortezomib-thalidomide-and-dexamethasone-vtd-induction-therapy.pdf
00566a	Carfilzomib in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	oral-anti-cancer-medicines, transplant, myeloma	carfilzomib and dexamethasone (kd) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/566-carfilzomib-and-dexamethasone-therapy.pdf
00595a	Carfilzomib in combination with dexamethasone is indicated forthe treatment of adult patients with multiple myeloma whohave received at least one prior therapy.	oral-anti-cancer-medicines, transplant, myeloma	carfilzomib (20/70mg/m2 once weekly) dexamethasone (kd) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/595-carfilzomib-20-70mg-m2-once-weekly-with-dexamethasone-kd-therapy.pdf
00598a	"Carfilzomib,  lenalidomide and dexamethasone therapy is indicated  for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy."	oral-anti-cancer-medicines, transplant, myeloma	carfilzomib (56mg/m2 once weekly) lenalidomide and dexamethasone (krd) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/598-carfilzomib-56mg-m2-once-weekly-lenalidomide-and-dexamethasone-krd-therapy-28-day.pdf
00405a	"Carfilzomib,  lenalidomide and dexamethasone therapy is indicated  for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy."	oral-anti-cancer-medicines, transplant, myeloma	carfilzomib (27mg/m2 twice weekly), lenalidomide and dexamethasone (krd) therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/405-carfilzomib-lenalidomide-and-dexamethasone-krd-therapy-28-day.pdf
00273a	"Treatment of newly diagnosed symptomatic multiple myeloma*.
Treatment of newly diagnosed symptomatic multiple myeloma."	oral-anti-cancer-medicines, transplant, myeloma	cyclophosphamide, bortezomib and dexamethasone (cybord) - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/273.pdf
00273b	"Treatment of relapsed/refractory multiple myeloma*.
Treatment of relapsed/refractory multiple myeloma."	oral-anti-cancer-medicines, transplant, myeloma	cyclophosphamide, bortezomib and dexamethasone (cybord) - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/273.pdf
00299a	Treatment of newly diagnosed symptomatic multiple myeloma.	oral-anti-cancer-medicines, transplant, myeloma	cyclophosphamide, bortezomib and dexamethasone (modified cybord) - weekly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/299-modified-cybord-bortezomib-cyclophosphamide-and-dexamethasone-%E2%80%93-weekly-therapy.pdf
00299b	Treatment of relapsed/refractory multiple myeloma.	oral-anti-cancer-medicines, transplant, myeloma	cyclophosphamide, bortezomib and dexamethasone (modified cybord) - weekly	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/299-modified-cybord-bortezomib-cyclophosphamide-and-dexamethasone-%E2%80%93-weekly-therapy.pdf
00426a	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.	oral-anti-cancer-medicines, transplant, myeloma	daratumumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/daratumumab monotherapy.pdf
00604a	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.	oral-anti-cancer-medicines, transplant, myeloma	daratumumab s/c	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/604-daratumumab-s-c-monotherapy.pdf
00560a	Daratumumab in combination with bortezomib and dexamethasone in adult patients with multiple myeloma who have received at least one prior therapy.	oral-anti-cancer-medicines, transplant, myeloma	daratumumab (iv), bortezomib and dexamethasone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/560-daratumumab-iv-bortezomib-and-dexamethasone-therapy1.pdf
00609a	Daratumumab in combination with bortezomib and dexamethasone in adult patients with multiple myeloma who have received at least one prior therapy.	oral-anti-cancer-medicines, transplant, myeloma	daratumumab (sc 1800mg), bortezomib and dexamethasone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/609-daratumumab-s-c-bortezomib-and-dexamethasone-therapy.pdf
00695a	Daratumumab in combination with bortezomib and dexamethasone in adult patients with mulitple myeloma who have received at least one prior therapy.	oral-anti-cancer-medicines, transplant, myeloma	daratumumab (sc 1800mg), bortezomib (weekly) and dexamethasone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/695-daratumumab-sc-1800mg-bortezomib-weekly-and-dexamethasone-therapy.pdf
00703a	"Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors."	oral-anti-cancer-medicines, transplant, myeloma	entrectinib, daratumumab sc, bortezomib, thalidomide and dexamethasone induction	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/703-daratumumab-bortezomib-thalidomide-and-dexamethsone-therapy.pdf
00755a	Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.	oral-anti-cancer-medicines, transplant, myeloma	daratumumab sc, bortezomib, thalidomide and dexamethasone consolidation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/755-daratumumab-sc-bortezomib-twice-weekly-thalidomide-and-dexamethasone-consolidation-therapy.pdf
00752a	Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.	oral-anti-cancer-medicines, transplant, myeloma	daratumumab (sc), bortezomib (once weekly), thalidomide and dexamethasone induction	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/752-daratumumab-sc-bortezomib-once-weekly-thalidomide-and-dexamethasone-induction-therapy.pdf
00756a	Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.	oral-anti-cancer-medicines, transplant, myeloma	daratumumab (sc), bortezomib (once weekly), thalidomide and dexamethasone consolidation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/756-daratumumab-sc-bortezomib-once-weekly-thalidomide-and-dexamethasone-consolidation-therapy.pdf
00516a	Ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	oral-anti-cancer-medicines, transplant, myeloma	ixazomib, lenalidomide and dexamethasone therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/516-ixazomib-lenalidomide-and-dexamethasone-therapy-28-day.pdf
00218a	Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.	oral-anti-cancer-medicines, transplant, myeloma	lenalidomide 25mg and dexamethasone therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/218-lenalidomide-25mg-and-dexamethasone-therapy-28-day.pdf
00218b	Treatment of multiple myeloma in adult patients who have received at least one prior therapy.	oral-anti-cancer-medicines, transplant, myeloma	lenalidomide 25mg and dexamethasone therapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/218-lenalidomide-25mg-and-dexamethasone-therapy-28-day.pdf
00454a	Conditioning Therapy in patients with Multiple Myeloma prior to autologous stem cell transplant.	oral-anti-cancer-medicines, transplant, myeloma	high dose melphalan conditioning therapy for autologous stem cell transplant	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/454-high-dose-melphalan-conditioning-therapy-for-autologous-stem-cell-transplant.pdf
00454b	Conditioning Therapy in patients with other plasma cell dyscrasia such as AL amyloidosis.	oral-anti-cancer-medicines, transplant, myeloma	high dose melphalan conditioning therapy for autologous stem cell transplant	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/454-high-dose-melphalan-conditioning-therapy-for-autologous-stem-cell-transplant.pdf
00245a	Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.	oral-anti-cancer-medicines, transplant, myeloma	pomalidomide and dexamethasone	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/245-pomalidomide-and-dexamethasone.pdf
00601a	Pomalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide.	oral-anti-cancer-medicines, transplant, myeloma	pomalidomide, bortezomib and dexamethasone (pvd)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/601-pomalidomide-bortezomib-and-dexamethasone-pvd-therapy.pdf
00327a	Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.	oral-anti-cancer-medicines, neuroendocrine	sunitinib 37.5mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/neuroendocrine/327-sunitinib-37-5mg-therapy.pdf
00379a	Adjuvant treatment of Grade II glioma administered after radiotherapy.	oral-anti-cancer-medicines, neuro-oncology	procarbazine lomustine and vincristine (pcv)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/379-pcv-therapy.pdf
00379b	Palliative treatment for recurrent high grade gliomas.	oral-anti-cancer-medicines, neuro-oncology	procarbazine lomustine and vincristine (pcv)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/379-pcv-therapy.pdf
00658a	Adjuvant treatment of Grade II glioma administered after radiotherapy.	oral-anti-cancer-medicines, neuro-oncology	procarbazine, lomustine and vincristine (pcv) therapy - 56 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/658.pdf
00742a	For the treatment of recurrent malignant glioblastoma.	oral-anti-cancer-medicines, neuro-oncology	lomustine and bevacizumab 5mg/kg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/742-lomustine-and-bevacizumab-5mg-kg-therapy.pdf
00334a	"Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation .
Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation."	oral-anti-cancer-medicines, neuro-oncology	temozolomide with radiotherapy (rt) and adjuvant therapy	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/334-temozolomide-with-radiotherapy-rt-and-adjuvant-therapy.pdf
00461a	"Adult patients greater than 65 years with newly-diagnosed glioblastoma multiforme not suitable for the standard radiotherapy regimen in combination with temozolomide ii.
Adult patients greater than 65 years with newly-diagnosed glioblastoma multiforme not suitable for the standard radiotherapy regimen in combination with temozolomide."	oral-anti-cancer-medicines, neuro-oncology	temozolomide with radiotherapy (rt) and adjuvant therapy-patients greater than 65 years	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/461temozolomide-with-radiotherapy-rt-and-adjuvant-therapy-patients-greater-than-65-years.pdf
00342a	"Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma,showing recurrence or progression after standard therapy."	oral-anti-cancer-medicines, neuro-oncology	temozolomide recurrent	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/342-temozolomide-recurrent-therapy.pdf
00482a	Treatment of advanced prostate cancer in combination with luteinizing-hormone releasing hormone (LHRH) analogue therapy or surgical castration.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	bicalutamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/482-bicalutamide-therapy.pdf
00373a	"Cobimetinib and vemurafenib in combination are indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Cobimetinib in combination with vemurafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation."	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	cobimetinib and vemurafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib and vemurafenib therapy.pdf
00237a	Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	dabrafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf
00563a	"Treatment of adult patients with advanced unresectable or metastatic) melanoma with a BRAF V600 mutation.
Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation."	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	encorafenib and binimetinib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf
00390a	In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	idelalisib and ofatumumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/390.pdf
00390b	In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	idelalisib and ofatumumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/390.pdf
00335a	"Treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)."	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	imatinib therapy-gist	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf
00335b	Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	imatinib therapy-gist	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf
00758a	For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	larotrectinib monotherapy - adult	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour agnostic therapy/758-larotrectinib-monotherapy-adult.pdf
P00760a	For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	larotrectinib monotherapy - paediatric	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour agnostic therapy/760 larotrectinib-monotherapy-paediatric.pdf
00468a	Autologous conditioning in non-Hodgkins Lymphoma (NHL).	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	leam autologous transplant conditioning protocol	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/468-leam-autologous-transplant.pdf
00468b	"Autologous conditioning in Hodgkins lymphoma.
Autologous conditioning in Hodgkins Lymphoma."	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	leam autologous transplant conditioning protocol	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/468-leam-autologous-transplant.pdf
00683	Midostaurin is indicated in combination with intermediate dose cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	midostaurin and intermediate dose cytarabine consolidation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/midostaurin-and-intermediate-dose-cytarabine-consolidation-therapy.pdf
00661	Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	midostaurin maintenance	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/midostaurin-maintenance-therapy.pdf
00445b	Treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	pazopanib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/445-pazopanib-therapy.pdf
00244b	Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	regorafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/244.pdf
00325a	Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	sunitinib 50mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/325-sunitnib-50mg-therapy.pdf
00719a	"Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due toresistance or intolerance."	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	sunitinib 50mg (21 days)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/sunitinib-50mg-therapysunitinib 50mg therapy .pdf
00415a	"Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation."	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	trametinib and dabrafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib and trametinib therapy.pdf
00102a	Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	vemurafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf
00236a	Treatment of adult patients with symptomatic metastatic basal cell carcinoma (MBCC).	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	vismodegib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/236.pdf
00236b	Treatment of adult patients with local advanced basal cell carcinoma inappropriate for surgery or radiotherapy.	transplant, tumour agnostic therapy, sarcoma, oral-anti-cancer-medicines, melanoma, paediatric	vismodegib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/236.pdf
P0567a	As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogenic hematopoietic stem cell transplantation.	paediatric	blinatumomab paediatric	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/567.pdf
P00707a	As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy.	paediatric	blinatumomab for relapsed paediatric all: consolidation	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/707-blinatumomab-rall-consolidation-therapy.pdf
P0548a	For the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neurobasltoma, any actively progressing disease should be stabilised by other suitable measures.	paediatric	dinutuximab beta and isotretinoin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/dinutuximab-v2-p548.pdf
00511a	Treatment of metastatic soft tissue sarcoma.	sarcoma	dacarbazine (1.2 g/m2) therapy - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/511-dacarbazine-1-2-g-m2-therapy-%E2%80%9321-day.pdf
00500a	Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.	sarcoma	doxorubicin 75mg/m2	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/500-doxorubicin-75mg-m2-monotherapy.pdf
00420a	Neoadjuvant/Adjuvant therapy of osteosarcoma.	sarcoma	doxorubicin (25mg/m2/day and cisplatin (100mg/m2) therapy - 21 day cycle	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/420-doxorubicin-25mg-m2-day-and-cisplatin-100mg-m2-therapy-21-day-cycle.pdf
00391a	Treatment of locally advanced unresectable or metastatic soft tissue sarcomas.	sarcoma	doxorubicin (60) and ifosfamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/391.pdf
00392a	Neoadjuvant treatment of high risk soft tissue sarcoma.	sarcoma	doxorubicin (75) and ifosfamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/392.pdf
00392b	Treatment of locally advanced unresectable or metastatic soft tissue sarcomas.	sarcoma	doxorubicin (75) and ifosfamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/392.pdf
00501a	Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.	sarcoma	gemcitabine and docetaxel therapy* - 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/501-gemcitabine-and-docetaxel-therapy-21-day.pdf
00675a	For the treatment of adolescents/young adults with newly diagnosed Ewing Sarcoma/ Ewing Family of tumours.	sarcoma	etoposide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/675-etoposide-and-ifosfamide-vincristine-doxorubicin-and-cyclophosphamide-ie-vac-therapy.pdf
00675b	For the treatment of adolescents/young adults with rhabdomyosarcoma or desmoplastic intra-abdominal small round blue cell tumour.	sarcoma	etoposide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/675-etoposide-and-ifosfamide-vincristine-doxorubicin-and-cyclophosphamide-ie-vac-therapy.pdf
00747a	For the treatment of adult patients with newly diagnosed Ewing Sarcoma/ Ewing Family of tumours.	sarcoma	etoposide and ifosfamide - vincristine, doxorubicin and cyclophosphamide (ie-vac) therapy - three weekly intervals	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/747-ie-vac-three-weekly.pdf
00747b	For the treatment of adult patients with rhabdomyosarcoma or desmoplastic intra-abdominal small round blue cell tumour.	sarcoma	etoposide and ifosfamide - vincristine, doxorubicin and cyclophosphamide (ie-vac) therapy - three weekly intervals	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/747-ie-vac-three-weekly.pdf
00596a	For the treatment of relapsed Ewing Sarcoma.	sarcoma	ifosfamide etoposide (ie)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/596-ifosfamide-etoposide-ie-therapy.pdf
00596b	For the treatment of osteosarcoma.	sarcoma	ifosfamide etoposide (ie)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/596-ifosfamide-etoposide-ie-therapy.pdf
00679a	High grade soft tissue sarcoma, retroperitoneal and de-differentiated sarcoma.	sarcoma	infusional ifosfamide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/679-infusional-ifosfamide-therapy.pdf
00463a	Neoadjuvant/Adjuvant therapy of localised or metastatic high grade osteosarcoma of an extremity/axial skeleton (excluding craniofacial sites)&amp;nbsp; -all disease sites amenable to complete surgical resection.	sarcoma	(map) methotrexate (12000mg/m2) doxorubicin (37.5mg/m2/day) and cisplatin (60mg/m2)	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/463-map-methotrexate-12000mg-m2-doxorubicin-37-5mg-m2-day-and-cisplatin-60mg-m2-therapy1.pdf
00100a	Treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults.	sarcoma	mifamurtide	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/100 .pdf
00205c	Metastatic soft tissue sarcoma.	sarcoma	pegylated liposomal doxorubicin 50mg/m2 (caelyx®) 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/205-pegylated-liposomal-doxorubicin-50mg-m2-caelyx-%C2%AE-28-days-regimen.pdf
00462a	Treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts ( &amp;lt; 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.	sarcoma	pegylated liposomal doxorubicin 20mg/m2 (caelyx®) 21 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/462.pdf
00374a	Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.	sarcoma	trabectedin	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/374.pdf
00554a	Treatment of advanced aggressive fibromatosis.	sarcoma	vinblastine and methotrexate	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/554-vinblastine-and-methotrexate-therapy.pdf
00535a	Treatment of adult patients with metastatic Merkel cell carcinoma who have received 1 or more lines of chemotherapy for metastatic disease.	melanoma	avelumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/535.pdf
00464a	Treatment of metastatic malignant melanoma.	melanoma	dacarbazine	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/464-dacarbazine-therapy.pdf
00105a	Treatment of adults with advanced (unresectable or metastatic) malignant melanoma.	melanoma	ipilimumab	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/105.pdf
00483a	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	melanoma	nivolumab 240mg monotherapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/483-nivolumab-240mg-monotherapy.pdf
00483f	As monotherapy for the adjuvant treatment of adults with melanoma withinvolvement of lymph nodes or metastatic disease who have undergonecomplete resection.	melanoma	nivolumab 240mg monotherapy - 14 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/483-nivolumab-240mg-monotherapy.pdf
00484a	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	melanoma	nivolumab 480mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf
00484c	As monotherapy for the adjuvant treatment of adults with melanoma withinvolvement of lymph nodes or metastatic disease who have undergonecomplete resection.	melanoma	nivolumab 480mg monotherapy - 28 days	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf
00431a	Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.	melanoma	nivolumab 1mg/kg ipilimumab 3mg/kg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/431-nivolumab-1mg-ipilimumab-3mg-therapy.pdf
00551b	Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.	melanoma	nivolumab 3mg/kg ipilimumab 1mg/kg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf
00455b	As monotherapy for the treatment of adults with unresectable or advanced melanoma.	melanoma	pembrolizumab 200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf
00455c	For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma.	melanoma	pembrolizumab 200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf
00455g	As monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.	melanoma	pembrolizumab 200mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf
00558b	As monotherapy for the treatment of adults with unresectable or advanced melanoma.	melanoma	pembrolizumab 400 mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/pembrolizumab-400mg-monotherapy-558.pdf
00558c	For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma.	melanoma	pembrolizumab 400 mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/pembrolizumab-400mg-monotherapy-558.pdf
00558g	Adjuvant treatment of adults with stage III melanoma and  lymph node involvement who have undergone complete resection.	melanoma	pembrolizumab 400 mg	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/pembrolizumab-400mg-monotherapy-558.pdf
00415b	Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.	melanoma	trametinib and dabrafenib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib and trametinib therapy.pdf
00639a	Myeloablative conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.	transplant	busulfan/cyclophosphamide-mac-mud	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/639.pdf
00641a	Myeloablative conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.	transplant	busulfan/cyclophosphamide - mac - sib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/641.pdf
00662a	Myeloablative conditioning for mismatched sibling donor allogeneic stem cell transplant in patients with myeloid disorders.	transplant	busulfan/cyclophosphamide/atg grafalon® - mac - mismatched sibling donor	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/662.pdf
00663a	Myeloablative conditioning for mismatched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.	transplant	busulfan/cyclophosphamide/atg grafalon® - mac - mismatched unrelated donor	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/663.pdf
00638a	Reduced intensity conditioning for sibling or matched unrelated allogeneic stem cell transplantation in Hodgkins and Non-Hodgkins Lymphoma.	transplant	carmustine/etoposide/cytarabine/melphalan/alemtuzumab ric-sib/mud	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/638.pdf
00631a	Myeloablative conditioning (MAC) for matched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.	transplant	cyclophosphamide/total body irradiation (tbi)-mac-mud	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/631.pdf
00637a	Myeloablative conditioning (MAC) for sibling donor allogeneic stem cell transplant in patients with lymphoid disorders.	transplant	cyclophosphamide/total body irradiation (tbi)-mac-sib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/637.pdf
00630a	Myeloablative conditioning (MAC) for mismatched sibling donor allogeneic stem cell transplant in patients with lymphoid disorders.	transplant	cyclophosphamide/total body irradiation (tbi)-mac-mismatched sibling donor	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/630.pdf
00629a	Myeloablative conditioning (MAC) for mismatched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.	transplant	cyclophosphamide/total body irradiation (tbi)-mac-mismatched unrelated donor	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/629.pdf
00635a	Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.	transplant	fludarabine/busulfan/atg grafalon® - ric - mud	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/635.pdf
00636a	Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.	transplant	fludarabine/busulfan/atg grafalon® - ric -sib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/636.pdf
00625a	Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with lymphoproliferative disorders.	transplant	fludarabine/melphalan/alemtuzumab-ric-mud	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/625.pdf
00611a	Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with lymphoproliferative disorders.	transplant	fludarabine/melphalan/alemtuzumab-ric-sib	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/611.pdf
00408a	Autologous conditioning in non-Hodgkins Lymphoma (NHL).	transplant	beam autologous transplant conditioning protoco	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/408.pdf
00408b	Autologous conditioning in Hodgkins Lymphoma.	transplant	beam autologous transplant conditioning protoco	https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/408.pdf
